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Abstract Several drugs are available for the management
of postmenopausal osteoporosis. This may, in daily prac-
tice, confuse the clinician. This manuscript offers an
evidence-based update of previous treatment guidelines,
with a critical assessment of the currently available efficacy
data on all new chemical entities which were granted a
marketing authorization. Osteoporosis is widely recognized
as a major public health concern. The availability of new
therapeutic agents makes clinical decision-making in osteo-
porosis more complex. Nation-specific guidelines are needed
to take into consideration the specificities of each and every
health care environment. The present manuscript is the result
of a National Consensus, based on a systematic review and a
critical appraisal of the currently available literature. It offers
an evidence-based update of previous treatment guidelines,
with the aim of providing clinicians with an unbiased
assessment of osteoporosis treatment effect.
Keywords Bisphosphonate.Osteoporosis.Raloxifene.
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Introduction
Osteoporosis is widely recognized as a major public health
concern. The cumulative lifetime fracture risk for a 50-year
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Belgium, the annual costs of osteoporotic fractures are
currently estimated in the range of 150 million euros, on a
societal perspective [2]. Effective fracture prevention would
have a major impact on women's morbidity and, to a lesser
extent, mortality. The availability of new therapeutic agents
has made clinical decision-making in osteoporosis more
complex [3]. Because individual clinicians cannot system-
atically collect all the evidence bearing on the efficacy of
osteoporosis therapies, they require summaries for consis-
tent therapeutic patterns [3]. As recommended by the
recently published European guidance for the diagnosis
and management of osteoporosis in postmenopausal women
[4], nation-specific guidelines are needed to take into
consideration the specificities of each and every health care
environment. The present document is the result of a
national consensus, based on a systematic review and a
critical appraisal of the currently available literature. It
offers an evidence-based update to previous Belgian Bone
Club treatment guidelines [5], with the aim of providing
clinicians with an unbiased assessment of osteoporosis
treatment effect. Currently in Belgium, reimbursement of
antiosteoporosis medications is granted to postmenopausal
womenwithlowbonemineraldensity(BMD;T-score<−2.5at
the lumbar spine or at the hip) or with a prevalent vertebral
fracture. Nevertheless, taking into account the new develop-
ment of validated tools, assessing the 10-year absolute fracture
risk of postmenopausal women, based on the presence of
clinicalriskfactors,it canreasonabilitybe expectedthat within
a few months or years, reimbursement of antiosteoporosis
medications will be open to all women who really deserve
treatment [6, 7]. These guidelines address only postmeno-
pausal women, and glucocorticoid-induced osteoporosis is
not included. Whereas most compounds have proven to
significantly reduce the occurrence of vertebral fractures,
discrepancies remain regarding the level of evidence related
to their nonvertebral or hip antifracture effect.
Methods
This paper expands and updates our previously published
Consensus [5]. We included meta-analyses or randomized
controlled trials (RCTs) in postmenopausal women, compar-
ing interventions currently registered in Belgium for the
management of osteoporosis with a placebo. However, for
some registered drugs like calcitonin and etidronate, the
reader is referred to our previous Consensus publication [5]
because no new data have been generated since and because
these drugs are no longer considered first-line treatment
options for the management of osteoporosis. The intervention
could be given in conjunction with a calcium and vitamin D
supplement, provided the comparison group received the
same supplements. Furthermore, the results had to be reported
with a follow-up of at least 1 year on one or more of the
outcomes of interest: radiological or clinical evidence of
fractures of the vertebra, wrist, or hip. We searched MED-
LINE from 1966 to 2009 and databases such as the Cochrane
Controlled Register for citations of relevant articles. After this
extensive search of the literature, a critical appraisal of the
data was obtained through a consensus experts meeting.
Calcium and vitamin D
Maintaining adequate calcium and vitaminD intake, through
diet modification and/or supplementation, is recommended
as part of standard care for osteoporosis. A recent expert
panel concluded that combined calcium and vitamin D
supplementation should be recommended in patients with
osteoporosis or those at increased risk of developing
osteoporosis[8]. Calcium and vitamin D reverses secondary
hyperparathyroidism with resultant beneficial effects on
bone density; additionally, calcium and vitamin D supple-
mentation significantly improves body sway and lower
extremity strength, reducing the risk of falls [9].
Calcium deficiency related to inadequate intake of
calcium leads to increased serum parathyroid hormone
(PTH) concentrations and bone loss. The guidelines issued
by the consensus conference of the National Institutes of
Health in the USA recommend a dietary intake of 1 g/day
in postmenopausal women on hormone-replacement thera-
py and 1.5 g/day in other postmenopausal women and in all
individuals over 65 years of age [10]. Although calcium
deficiency can be corrected by adjusting the dietary intake
of calcium, most individuals—and particularly older wom-
en at risk of osteoporosis—are unable or unwilling to
change their lifestyle practices and will require calcium
supplementation. In line with the assumption that calcium
as citrate is better absorbed than calcium as carbonate in the
fasting state, a recent comparative trial concluded that the
use of calcium citrate may reduce bone resorption at lower
doses than calcium carbonate, lead to less adverse effects,
and potentially improve long-term compliance [11, 12].
Several serum 25-hydroxyvitamin D (25(OH)D) cut-offs
have been proposed to define vitamin D insufficiency (as
opposed to adequate vitamin D status), ranging from 30 to
100 nmol/l. Based on the relationship between serum 25
(OH)D, BMD, bone turnover, lower extremity function, and
falls, 50 nmol/l is likely to be the appropriate serum
25(OH)D threshold to define vitamin D insufficiency [13].
Supplementation should therefore generally aim to increase
25(OH)D levels within the 50–75-nmol/l range. In most
individuals, this level can be achieved with a dose of
800 IU/day vitamin D, the dose that was used in successful
fracture prevention studies to date; a randomized clinical
trial assessing whether higher vitamin D doses achieve a
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considerable interest.
T h ee f f i c a c yo fc o m b i n e dc a l c i u ma n dv i t a m i nD
supplementation in reducing nonvertebral fracture rates
has been demonstrated in three large, randomized,
placebo-controlled, multicenter studies. Two of these
studies involved institutionalized elderly patients, the
Decalyos I [14, 15] and Decalyos II [16] studies, and one
involved community-living elderly patients [17].
Decalyos I enrolled 3,270 women, aged 69–106 years
(mean, 84 years), all of whom were able to at least walk
indoors with a cane [14]. All had inadequate dietary
calcium intake (<800 mg/day; mean, 513 mg/day) at study
entry, while 44% had vitamin D insufficiency—serum 25
(OH)D level <30 nmol/ml, by radioimmunoassay (RIA).
Randomization was 1:1 to 1,200 mg of calcium as
tricalcium phosphate plus 800 IU of vitamin D daily (n=
1,634) or to double placebo (n=1,636). In the women
completing 18 months' therapy (n=1,765), supplementation
reduced hip fracture incidence by 43% (risk ratio (RR),
0.57; 95% confidence interval (CI) not indicated; p=0.043)
and nonvertebral fracture incidence by 32% (RR, 0.68; 95%
CI not indicated; p=0.015) [14]. Similar benefits were seen
in the intention-to-treat analysis. The reduction in hip
fracture risk was apparent after 10 months' therapy, while
an effect on all nonvertebral fractures was seen within
2 months. Furthermore, it was noted that the incidence of
hip fracture increased markedly with time in the placebo
group but remained stable in the calcium and vitamin D
group. Changes in BMD at the proximal femur at 18 months
(+2.7% in calcium and vitamin D group vs. −4.6% in the
placebo group) were consistent with the reported differ-
ences in fracture risk between the two treatment groups
[14]. Similar differences were seen in BMD at the femoral
neck and in the trochanteric region. Secondary hyperpara-
thyroidism also improved in the supplement group, with the
majority of the improvement noted within 6 months. Further
analysis of Decalyos I at 36 months' follow-up confirmed
the continued preventive effect of calcium and vitamin D
on fracture risk. For patients remaining on treatment, risk of
hip and nonvertebral fractures continued to be significantly
reduced (RR, 0.61 and 0.66, respectively; 95% CI not
indicated; both p<0.01). In the intent-to-treat analysis,
similar risk reductions were observed (RR, 0.77 and 0.83,
respectively; 95% CI not indicated; both p<0.02) [15].
Decalyos II had a similar design to Decalyos I, with the
exception that randomization was 2:1 to calcium and
vitamin D vs. placebo and that the study duration was
2 years [16]. Of the 639 enrolled patients (610 random-
ized), 66% had an inadequate intake of both calcium
(<800 mg/day) and vitamin D (serum 25(OH)D level (by
RIA) <30 nmol/ml). Hip fractures occurred in 27 out of 393
(6.9%) women in the calcium and vitamin D group,
compared with 21 out of 190 (11.1%) in the placebo group.
The difference in the cumulative probability of hip fracture
did not achieve statistical significance (RR, 0.69; 95% CI
not indicated; p=0.07). Hip fracture risk was reduced in the
calcium and vitamin D group from about 9 months, a
finding consistent with that in Decalyos I. The magnitude
of reduction in hip fracture risk was also similar to that seen
in Decalyos I. The incidence of nonvertebral fractures was
comparable in the two treatment groups. Femoral neck
BMD remained unchanged in the calcium and vitamin D
group (mean change, +0.29%/year) but decreased in the
placebo group (−2.36%/year). The mean difference be-
tween the two treatment groups was not statistically
significant (95% CI, 0.44–5.75%). Biochemical indices of
calcium homeostasis normalized within 6 months of
commencement of supplementation.
In contrast to the Decalyos studies, the study by
Dawson-Hughes et al. [17] involved healthy, elderly,
ambulatory men and women aged over 65 years (n=389;
mean age, 71 years) living in the community. Levels of
insufficiency were not as profound as those documented in
the Decalyos studies. Randomization was 1:1 to calcium
500 mg as calcium citrate malate plus vitamin D 700 IU or
placebo, with follow-up and treatment planned for 3 years.
Nonvertebral fractures were sustained by 11 (5.6%) patients
in the calcium and vitamin D group, compared with 26
(13.3%) in the placebo group (RR of first fracture, 0.5; 95%
CI, 0.2–0.9; p=0.02). As in the Decalyos studies, supple-
mentation also led to significant improvements in biochem-
ical parameters and BMD.
Results of trials assessingfracture reductionwithvitamin D
alone have been equivocal [18–20]. In a recent randomized,
double-blind, placebo-controlled study, vitamin D
100,000 IU every 4 months reduced the risk of first hip,
wrist or forearm, or vertebral fractures by 33% (RR, 0.67;
95% CI, 0.48–0.93; p=0.02) [19]. Similarly, in a controlled
trial in elderly Finnish subjects, annual intramuscular
injections of high doses of vitamin D (150,000–300,000 IU)
reduced fracture rates by approximately 25% (RR, 0.75; 95%
CI not indicated; p=0.03) [20], although the benefits were
limited to fractures of the upper limbs and ribs and to women
only. No reduction in the risk of hip fractures was seen in a
randomized, double-blind, placebo-controlled trial of vitamin
D (400 IU/day) alone in an elderly community-dwelling
population (n=2,578; mean age, 80 years) in the Netherlands
(RR, 1.18; 95% CI, 0.81–1.71; p=0.31) [18].
More recently, meta-analyses have confirmed that the
combination of calcium and vitamin D supplementation
decreases the fracture risk for postmenopausal women [21,
22]. The analyses provided evidence that these beneficial
effects were not attributable to either calcium or vitamin D
alone with, for example, Bischoff-Ferrari et al. and Boonen
et al., suggesting that oral vitamin D appears to reduce the
Osteoporos Int (2010) 21:1657–1680 1659risk of hip fractures only when calcium supplementation is
added [21, 22].
In the meta-analysis by Bischoff-Ferrari et al., the
effectiveness of vitamin D supplementation in preventing
hip and nonvertebral fractures in older persons was
estimated [21]. Heterogeneity among studies for both hip
and nonvertebral fracture prevention was observed, which
disappeared after pooling RCTs with low-dose (400 IU/
day) and higher-dose vitamin D (700–800 IU/day), sepa-
rately. A vitamin D dose of 700 to 800 IU/day reduced the
relative risk (RR) of hip fracture by 26% (three RCTs with
5,572 persons; pooled RR, 0.74; 95% CI, 0.61–0.88) and
any nonvertebral fracture by 23% (five RCTs with 6,098
persons; pooled RR, 0.77; 95% CI, 0.68–0.87) vs. calcium
or placebo. No significant benefit was observed for RCTs
with 400 IU/day vitamin D (two RCTs with 3,722 persons;
pooled RR for hip fracture, 1.15; 95% CI, 0.88–1.50;
pooled RR for any nonvertebral fracture, 1.03; 95% CI,
0.86–1.24), supporting the concept that vitamin D supple-
mentation between 700 and 800 IU/day reduces fracture
risk in elderly persons and that an oral vitamin D dose of
400 IU/day is not sufficient for fracture prevention. In a
more recent meta-analysis on the efficacy of oral supple-
mental vitamin D in preventing nonvertebral and hip
fractures, Bischoff-Ferrari et al. confirmed that fracture
prevention with vitamin D is dose dependent [23].
Boonen et al. analyzed over 45,000 patients from six
randomized placebo-controlled trials to examine the effect
of combined vitamin D with calcium supplementation in
hip fracture prevention [22]. The pooled RR for hip fracture
was 0.82 (95% CI, 0.71–0.94), showing a significant 18%
risk reduction with the combined use of calcium and
vitamin D supplementation compared with no supplemen-
tation. An adjusted indirect comparison for combined
calcium and vitamin D supplementation also demonstrated
a statistically significant 25% reduction in hip fracture risk
with calcium and vitamin D compared with vitamin D
alone (95% CI, 0.58–0.96). Taken together, these analyses,
designed to extend the findings of Bischoff-Ferrari et al.
[21], provided evidence that oral vitamin D appears to reduce
the risk of hip (and any nonvertebral) fractures only when
calcium is added. Thus, to optimize clinical efficacy, vitamin
D 700–800 IU/day should be complemented with calcium,
using a dose of 1,000–1,200 mg/day of elemental calcium.
The meta-analysis by Tang et al. evaluated almost
64,000 patients aged 50 years or older from 29 randomized
trials to assess calcium or calcium in combination with
vitamin D for the prevention of fracture and osteoporotic
bone loss [24]. Supplementation was associated with a 12%
reduction in all fractures, which was greater in trials with
higher compliance. In trials that reported BMD, reduced
rates of bone loss of 0.54% (95% CI, 0.35–0.73; p<0.001)
at the hip and 1.19% (95% CI, 0.76–1.61; p<0.001) at the
spine were reported in association with supplementation.
For the best therapeutic effect, the authors recommended
minimum doses of 1,200 mg of calcium and 800 IU of
vitamin D.
Combined supplementation has also been recommended
as an effective adjunct to osteoporosis therapy. In elderly
patients taking bisphosphonates for the treatment of
osteoporosis, studies have demonstrated an incremental
benefit of vitamin D on BMD at the lumbar spine [8]. More
recent evidence for the role of calcium and vitamin D as an
essential component of the medical management of osteo-
porosis came from the ICARO study, a multicenter,
observational study [25]. The study has been designed to
analyze, in postmenopausal women with established oste-
oporosis, the risk factors for an “inadequate clinical
response” to drug therapy, defined as the occurrence of
new vertebral or nonvertebral fragility fractures in patients
prescribed, for at least 1 year, alendronate, risedronate, or
raloxifene (RAL), with a compliance over 50%. In 880
patients treated with antiresorptive agents for a median of
2.0 (95% CI, 1.0–4.5)years, the incidence of fractures
during treatment with antiresorptive agents in a clinical
setting is considerably higher than that observed in
randomized clinical trials. Moreover, in adjusted analyses,
inadequate compliance to treatment and lack of supplemen-
tation of calcium and vitamin D were found to be major
determinants of this poor response.
Calcium and vitamin D supplementation is frequently
perceived by patients and sometimes by their physicians as
an excessive medication and is easily dismissed to avoid
polypharmacy, especially in elderly patients. Lack of
motivation is the most common reason for nonadherence
to calcium and vitamin D3 supplementation, emphasizing
the need for an active role of physicians in prescribing
supplements and motivating patients [26].
In conclusion, calcium and vitamin D should be consid-
ered as an essential (but not sufficient) component of the
treatment of osteoporosis, although most patients will derive
further benefit in terms of fracture prevention from the
addition of an antiresorptive or anabolic agent. However,
antifracture efficacy with antiresorptive or anabolic osteopo-
rosis medications has only been documented in calcium and
vitamin D supplemented individuals. The available evidence
suggests that, in many patients, combined supplementation
with 1,000–1,200 mg of elemental calcium and 800 IU of
vitamin D may be required.
Hormone replacement therapy
Estrogen deficiency is the most frequent risk factor for
osteoporosis. Although randomized trials provide strong
evidence that bone loss can effectively be prevented even
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(HRT) and that fracture risk can be reduced with conven-
tional doses, even in postmenopausal women who do not
suffer from osteoporosis [27], the consensus has changed
since the Women Health Initiative (WHI) studies. These
randomized controlled trials evaluated, however, only two
regimens of HRT: either the daily dose of 0.625 mg
conjugated equine estrogen (CEE) alone in hysterectomized
women or CEE combined with medroxyprogesterone
acetate in women with an intact uterus. Following the first
publications of these studies, HRT is no longer recom-
mended as a first-line therapy for osteoporosis. Indeed, the
WHI studies have reported that prolonged use of HRT
especially in elderly women pertains an increased risk of
breast cancer, thromboembolic disease, and cerebrovascular
accidents [28], confirming that the presence of a history of
one of these affections should be considered as an absolute
contraindication to HRT prescription and that the presence
of important risk factors of breast cancer, thromboembolic
disease, and cerebrovascular accidents should be viewed as
relative contraindications. The latter two risks may be lower
when using a transdermal administration of estrogen rather
than an oral one, and especially so in women with a genetic
predisposition of thrombosis [29, 30]. Similarly, tibolone
should not be viewed as a first line therapy for osteoporosis
treatment. In an RCT in elderly women suffering from
osteoporosis at the hip or spine or osteopenia and radiologic
evidence of a vertebral fracture, Cummings et al. [31]
evaluated tibolone (1.25 mg/day, i.e., half the conventional
dosis) as compared to placebo. After a median time of
34 months of treatment, the tibolone group, as compared
with the placebo group, had a decreased risk of vertebral
fracture (70 cases vs. 126 cases per 1,000 person-years; RR,
0.55; 95% CI, 0.41–0.74; p<0.001) and a decreased risk of
nonvertebral fracture (122 cases vs. 166 cases per
1,000 person-years; RR, 0.74; 95% CI, 0.58–0.93; p=
0.01). Interestingly the tibolone group also had a decreased
risk of invasive breast cancer (RR, 0.32; 95% CI, 0.13–
0.80; p=0.02) and colon cancer (RR, 0.31; 95% CI, 0.10–
0.96; p=0.04). However, because the tibolone group had an
increased risk of stroke (RR, 2.19; 95% CI, 1.14–4.23; p=
0.02), the study was stopped prematurely.
Although prolonged use of HRT may reduce the risk of
fracture in healthy postmenopausal women, these data have
to be strongly weighted against the other reported effects of
HRT on disease outcomes (breast cancer risk, thromboem-
bolic disease, risk of stroke, etc.) and with the possibility of
treating women for osteoporosis with other therapeutic
regimens [32]. Given these possibilities, our view is that,
currently, HRT should not be prescribed for osteoporosis in
women who do not experience menopausal symptoms. In
symptomatic women, the potential adverse effects should
be explained, and the treatment should be prescribed for
short periods of time. Indeed, Lekander et al. [33], using a
Markov cohort simulation model and using results taken
from the WHI and containing hip, vertebral, and wrist
fracture, breast and colorectal cancer, coronary heart
disease, stroke, and venous thromboembolic events, found
that it was cost-effective to treat women with menopausal
symptoms with HRT and even where symptoms were mild
HRT remained cost-effective [33]. The question remains
unanswered whether HRT prescribed for a few years to
suppress menopausal symptoms offers also long-lasting
benefits for the prevention of postmenopausal bone loss and
osteoporotic fracture. While most observational studies
reported that past HRT users had the same osteoporosis
risk as never users after a few years of HRT withdrawal,
Bagger et al. [34] reported in 347 healthy postmenopausal
women with normal bone mass who had earlier participated
in placebo-controlled HRT trials that compared to placebo-
treated women, HRT-treated women had a significantly
reduced risk of osteoporotic fractures (RR=0.48 (95% CI,
0.26–0.88)). There are only short-term randomized trials
available about the effect of phytoestrogens on osteoporo-
sis. Most of these data evaluated either the bone turnover or
the modification of the bone mass, and they have found
inconsistent results. With the exception of a prospective
trial assessing the effects of ipriflavone on osteoporotic
fractures, which concluded in an absence of significant
effect [35], we were unable to find randomized trials that
evaluated the fracture efficacy of phytoestrogens [36–40].
In conclusion, when prescribing HRT, benefits need to
be balanced against potential risks, and these should be
explained to women. Although HRT significantly decreases
bone loss and risk of osteoporotic fractures, its main
indication in postmenopausal women remains the relief of
menopausal symptoms. In younger women (50–59-year-old
women), and when used during short periods of time (less
than 5 years), the risk of stroke and of breast cancer are
mild, and a “window of opportunity” for a benefit in
cardiovascular disease may even exist.
Selective estrogen-receptor modulators
Since the publication of our former evidence-based guide-
lines for the treatment of postmenopausal osteoporosis [5],
few papers dealing with selective estrogen-receptor modu-
lators (SERMs) have been published.
In a meta-analysis taking into account data from the
studies with RAL therapy in which vertebral fractures were
prospectively collected, it was shown that in seven clinical
studies pooled together, RAL 60 mg reduced the risk for
vertebral fracture by 40% (RR, 0.60; 95% CI, 0.49–0.74)
and RAL 120/150 mg by 49% (RR, 0.51; 95% CI, 0.41–
0.64) [41]. A tentative trial aimed at comparing the
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opausal women with low bone mass had to be stopped after
1 year, due to the too slow enrolment of treatment-naïve
women to meet the planned timeline [42]. This resulted in
insufficient power to demonstrate non-inferiority between
treatments. When the study was stopped, the women were
in the study for a mean of 312 days and a median of
190 days, without any significant difference in treatment
duration nor in incidence of vertebral and nonvertebral
fractures between the treatment groups [42]. No difference
in adverse events leading to treatment discontinuation was
observed either. The only adverse events significantly more
frequent in the alendronate group as compared to the RAL
group (p<0.05) were colonoscopy (1.1% vs. 0.1% of
women), diarrhea (3.8% vs. 1.0%), and nausea (5.3% vs.
3.1%). Women with ≥1 hot flush or leg cramp were more
numerous in the RAL group than in the alendronate group
(10.3% vs. 7.3%; p=0.049), whereas women with ≥1
upper gastrointestinal adverse event were more numerous
in the alendronate group (14.5% vs. 10.9%; p=0.046)
[42].
The Continuing Outcomes Relevant to Evista (CORE)
trial was planned as a 3-year extension of the Multiple
Outcomes of Raloxifene Evaluation (MORE) trial in a
double-blind mode [43, 44]. This study was started on
average 10.6 months after the end of the MORE study,
because the code could evidently not be broken immedi-
ately at the end of the MORE study. Four thousand eleven
women could resume the very same treatment assigned at
the start of MORE in a double-blind manner with the
exception that only the 60-mg dose of RAL was compared
with placebo. The patients initially assigned to the 120-mg
dose in MORE continued on 60 mg in CORE. The primary
objective of CORE was to evaluate the risk of breast cancer
[43], with peripheral, but not the vertebral fractures,
recorded as adverse effects. Furthermore, other treatments
aimed at improving bone status were allowed, bisphosph-
onate therapy being more frequent in the former RAL
group than in the placebo group. Only 386 women took no
bone-acting drug during 8 years, and 259 were on RAL.
The latter ones maintained their BMD values both at the
spine and at the hip [44]. After 8 years (4 years in MORE,
3 years in CORE, plus nearly 1 year in between without
SERM therapy), RAL therapy led to BMDs higher by 2.2%
at the spine and by 3% at the total hip, comparatively with
placebo. There was no statistically significant difference in
the incidence of nonvertebral fractures between both groups
[44]. In a post hoc analysis, the risk of new nonvertebral
fractures at six skeletal sites (clavicle, humerus, wrist,
pelvis, hip, and lower leg) was statistically significantly
decreased in CORE patients suffering from prevalent
vertebral fractures at MORE baseline and in women with
semiquantitative grade 3 vertebral fractures in the combined
MORE and CORE trials on RAL [44]. It is interesting to
note that during the time interval between the end of
MORE and the start of CORE (on average 337±85 (SD)
days), a significant bone loss was observed at the spine and
the femoral neck in the RAL group, correlated at the spine
with the length of time off of study drug [44]. Moreover, in
another study, treatment discontinuation for 1 year after
5 years of continuous therapy with RAL was also
accompanied with significant BMD declines both at the
lumbar spine (−2.4±2.4%) and the hip (−3.0±3.0%), an
effect comparable with estrogen weaning [45]. There is no
data available, however, on fracture incidence following
RAL discontinuation [45].
At the end of the 8-year study period of MORE+CORE,
the reduction in invasive breast cancer amounted to 66%
(RR, 0.34; 95% CI, 0.22–0.50) and in invasive estrogen-
receptor-positive breast cancers to 76% as compared with
placebo (RR, 0.24; 95% CI, 0.15–0.40) [43]. In contrast,
there was no statistically significant difference in the
incidence of invasive estrogen-receptor-negative breast
cancer between groups. Regardless of invasiveness, the
overall incidence of breast cancer decreased by 58% in the
RAL group (RR, 0.42; 95% CI, 0.29–0.60) compared with
the placebo group. Endometrial tolerance (hyperplasia,
cancer, or vaginal bleedings) was not different from placebo
[43]. A nonsignificant increase in the risk of deep venous
thrombosis persisted in the CORE study (RR, 2.17; 95%
CI, 0.83, 5.70) [43].
In another study vs. placebo, concerning 10,101 post-
menopausal women (mean age, 67.5 years) with coronary
heart disease or multiple risk factors for coronary heart
disease, RAL (60 mg/day) did not modify significantly the
risk of primary coronary events but confirmed a reduction
in the risk of invasive breast cancer (RR, 0.56; 95% CI,
0.38–0.83) [46]. The risk of clinical vertebral fractures (RR,
0.65; 95% CI, 0.47–0.89) was also reduced. However, RAL
therapy was associated with an increased risk of fatal stroke
(RR, 1.49; 95% CI, 1.0–2.24) and venous thromboembo-
lism (RR, 1.44; 95% CI, 1.06–1.95). In the STAR study
involving 19,647 postmenopausal women with increased
5-year breast cancer risk, RAL was shown to be as effective
as tamoxifen in reducing the risk of invasive breast cancer
[47]. In this study, RAL demonstrated a lower risk of
thromboembolic events and cataracts, but a nonsignificant
higher risk of noninvasive breast cancer as compared with
tamoxifen [47].
In conclusion, RAL at a daily dose of 60 mg is able to
prospectively induce a significant decrease in the vertebral
fracture risk in postmenopausal women with both densito-
metric osteoporosis (T-score≤−2.5) and established osteo-
porosis. Data on nonvertebral fracture are only positive in
post hoc analyses in a subgroup of patients with prevalent
vertebral fractures. Another clinical advantage is that a
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receptor-positive invasive breast cancers was observed,
similar to that conferred by tamoxifen. On the other hand,
RAL does not confer any cardiovascular prevention. On the
contrary, it provoked a small but significant increase in the
risk of fatal stroke as well as of venous thromboembolism.
In his decision for antiosteoporotic therapy with RAL, the
clinician should weigh the benefits observed on the
reduction in invasive breast cancer and vertebral fracture
risk and the drawbacks of this treatment, which are the lack
of effect on nonvertebral fracture risk, and the increased
risks of venous thromboembolism and fatal stroke.
Bisphosphonates
Alendronate, risedronate, ibandronate, and zoledronic acid
(ZA) are currently registered in Belgium for the treatment
of osteoporosis. Oral bisphosphonates may be associated
with gastrointestinal complaints, and therapeutic schemes
are mandatory constraining. Inconvenience and complexity
of required dosing procedures with oral bisphosphonate
therapy are factors that hinder medication persistence
leading to suboptimal health care outcomes. These are
reasons why alternative approaches have been developed.
Repeated infusions of potent bisphosphonates at large time
intervals could circumvent these constraints and greatly
simplify the current treatment of osteoporosis.
The antifracture efficacy of alendronate has been
established in large populations of postmenopausal women
[48–50]. In the study including 2,027 women with prevalent
vertebral fracture(s) at baseline, alendronate reduced the
incidence of new vertebral fractures by 47% (RR, 0.53; 95%
CI, 0.41–0.68) [49]. The incidence of vertebral fractures
with clinical symptoms was similarly reduced (RR, 0.46;
95% CI, 0.28–0.75). There was no reduction in the overall
risk of nonvertebral fractures (RR, 0.80; 95% CI, 0.63–
1.01), but hip fracture incidence was also reduced (RR,
0.49; 95% CI, 0.23–0.99) as was wrist fracture risk (RR,
0.52; 95% CI, 0.31–0.87) [49]. Estimation of the effect on
hip fracture was not precise and the CI correspondingly
wide, reflecting that the number of fractures (33 in total)
was small. The antifracture efficacy of alendronate was also
demonstrated in 4,432 women with low bone mass but
without vertebral fractures at baseline treated for 4 years
(5 mg daily during the first 2 years, then 10 mg daily). The
reduction in the incidence of radiological vertebral fractures
was 44% (RR, 0.56; 95% CI, 0.39–0.80). However, the
reduction in clinical fractures was not statistically significant
in the whole group but well among women with initial
T-scores below −2.5 at the femoral neck (RR, 0.64; 95% CI,
0.50–0.82). No reduction was observed in the risk of
nonvertebral fractures (RR, 0.88; 95% CI, 0.74–1.04) [50].
The effect of alendronate on nonvertebral fractures has
been best estimated in a meta-analysis of five placebo-
controlled trials of at least 2 years duration including
postmenopausal women with a T-score<−2.0. The estimat-
ed cumulative incidence of nonvertebral fractures after
3 years was 12.6% in the placebo group and 9.0% in the
alendronate group (RR, 0.71; 95% CI, 0.502–0.997) [51].
Another meta-analysis estimated that alendronate reduced
vertebral fracture incidence by 48% when given at 5 mg
daily or more (RR, 0.52; 95% CI, 0.43–0.65) and non-
vertebral fracture rate by 49% when given at 10 mg daily or
more (RR, 0.51; 95% CI, 0.38–0.69) [52]. However, data
from one of the largest trials with alendronate [53] were
excluded from this meta-analysis [52]. Data on BMD and
biochemical markers of bone remodeling have been
reported from patients discontinuing alendronate treatment
after 3 to 5 years or continuing for 10 years [53, 54]. As
primary outcome, women who discontinued alendronate
showed, after 5 years, a 3.7% (95% CI, 3–4.5) and 2.4%
(95% CI, 1.8–2.9) decline in lumbar and hip BMD,
respectively, as compared with patients continuing alendr-
onate [54]. Similarly, biochemical markers gradually
increased over 5 years in patients discontinuing alendronate
(55.6% for serum C-terminal telopeptide of type 1 collagen
(sCTX) and 59.5% for N-propeptide of type 1 collagen).
There was no evidence that discontinuation of alendronate
for up to 5 years increases fracture risk, but the optimal
duration of treatment remains unknown, although these data
provide evidence for 10 years safety of alendronate therapy.
Alendronate was well tolerated in these different
placebo-controlled trials, but patients at risk for upper
gastrointestinal events were excluded from the trials, and
subsequent experience has undoubtedly demonstrated that
esophageal and, to a lesser extent, gastric toxicity can be
troublesome adverse events, especially if proper intake
instructions are not respected. Several cases of esophageal
ulcerations have thus been described [55].
Daily compliance with 10 mg alendronate is uncertain
and difficult to maintain in routine clinical practice. The
efficacy and safety of treatment with oral once-weekly
alendronate 70 mg, twice-weekly alendronate 35 mg, and
daily alendronate 10 mg have been compared in a double-
blind, 1-year study involving a total of 1,258 postmeno-
pausal osteoporotic women. The increases in BMD at the
lumbar spine, hip, and total body were similar for the three
dosing regimens, and the fall in bone turnover markers was
also quite similar. The gastrointestinal tolerance of the
once-weekly regimen and the daily dosing were similar
[55]. The antifracture efficacy of the weekly formulation is
supposed to be similar to the daily formulation, but this has
not been formally tested.
Generic alendronate sodium tablets are now available
with a theoretical bioequivalence to the branded product.
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with generic formulations of alendronic acid 70-mg tablets
have been reported [56, 57]. Some concern remains for the
clinician that the pharmaceutical properties of the various
generic formulations may affect the potential for esophageal
irritation and tolerability, the bioavailability, and the potency
of generic alendronate [58]. In a retrospective 1-year
observational analysis, the persistence of patients treated
with generic alendronate and the increases of lumbar spine
and total hip BMD were significantly lower as compared to
each of the two originals branded alendronate and risedro-
nate [59]. The question of lower bioavailability or potency
of generic alendronate remains open.
Risedronate at the dose of 5 mg daily for 3 years has
been shown to significantly reduce the vertebral fracture
risk in established osteoporosis as compared with placebo.
In women with at least one vertebral fracture at baseline,
the relative reduction of new vertebral fractures was 41%
(RR, 0.59; 95% CI, 0.42–0.82) and 39% for nonvertebral
fractures (RR, 0.61; 95% CI, 0.39–0.94) [60]. In women
with at least two vertebral fractures at baseline, the risk of
new vertebral fractures was reduced by 49% (RR, 0.51;
95% CI, 0.36–0.73) but, in this study, the effect on new
nonvertebral fractures was not significant (RR, 0.67; 95%
CI, 0.44–1.04) [61]. Pooling of both studies showed that
after 1 year of treatment, the risk of new vertebral fracture
was reduced by 62% (RR, 0.38; 95% CI, 0.25–0.56) and of
multiple new vertebral fractures by 90% (RR, 0.10; 95%
CI, 0.04–0.26) [62]. Reduction of clinical vertebral frac-
tures and nonvertebral fractures has been reported within
6 months of risedronate treatment [63]. The European study
[61] was continued blindly in a subset of the population,
and the antifracture efficacy was maintained for at least
5 years [64], the longest available double-blind fracture
data for an antiresorptive. Vertebral fracture risk reduction
with risedronate was confirmed in women over 80 with
documented osteoporosis (RR, 0.56; 95% CI, 0.39–0.81),
providing post hoc evidence that even in patients 80 years
of age or older, reducing bone resorption rate remains an
effective osteoporosis treatment strategy [65].
Risedronate has also been shown to decrease the
incidence of hip fractures in a controlled trial specifically
designed for that purpose. Hip fracture reduction was only
observed in women with documented osteoporosis, how-
ever. In this placebo-controlled study involving 5,445
women 70–79 years old who had osteoporosis and risk
factors for falls, it was shown that risedronate at 2.5 or
5 mg/day for 3 years (the actual mean duration of treatment
was 2 years) lowered the RR of hip fracture by 40% (RR,
0.60; 95% CI, 0.40–0.90). There was no dose effect and,
interestingly, the effect was greater in the group of women
who had a vertebral fracture at baseline (RR, 0.40; 95% CI,
0.20–0.80). In the same study, however, there was no
significant effect of risedronate in 3,886 women ≥80 years
old (RR, 0.80; 95% CI, 0.60–1.20), but these patients were
essentially selected on the basis of the presence of at least
one risk factor for hip fracture, such as difficulty standing
from a sitting position and a poor tandem gait, rather than
on the basis of low BMD or prevalent fractures [66]. The
antifracture efficacy of risedronate has been confirmed in a
meta-analysis [67]. The pooled RR for vertebral fractures in
women given 2.5 mg or more of risedronate daily was 0.64
(95% CI, 0.54–0.77), whereas for nonvertebral fractures, it
was 0.73 (95% CI, 0.61–0.87). Like alendronate, risedro-
nate also had a safe profile in clinical trials. The safety
profile of risedronate was similar to that of placebo, despite
the fact that unlike in the alendronate trials, patients with a
history of gastrointestinal disease or chronic use of
nonsteroidal anti-inflammatory drugs were not excluded
from the risedronate studies. A weekly formulation of
risedronate has also been developed and, as for alendronate,
has been shown to be therapeutically equivalent to the daily
formulation as judged by the effects on bone density and on
bone turnover [68].
The iBandronate Osteoporosis trial in North America
and Europe (BONE) has been the first study to prospec-
tively demonstrate a reduction of vertebral fracture risk on
an intermittent bisphosphonate regimen [69]. A 2.5-mg
daily oral ibandronate and an intermittent oral ibandronate
dosage (20 mg every other day for 12 doses every 3 months)
were assessed in a 3-year placebo-controlled trial including
2,946 osteoporotic women with prevalent vertebral fracture.
The RR reductions of new morphometric vertebral fracture,
compared with placebo, were 62% (RR, 0.38; 95% CI,
0.25–0.59) and 50% (RR, 0.50; 95% CI, 0.34–0.74) for the
daily and intermittent groups, respectively. The incidence
of nonvertebral fractures was similar between the ibandr-
onate and placebo groups after 3 years (9.1%, 8.9%, and
8.2% in the daily, intermittent, and placebo groups,
respectively; difference between arms was not significant).
The overall population was at low risk for osteoporotic
fractures (mean total hip BMD T-score, −1.7), but post
hoc analysis, in higher-risk subgroups, showed that the
daily regimen reduced the risk of nonvertebral fractures
(femoral neck BMD T-score<−3.0, 69%; p=0.012; lumbar
spine BMD T-score<−2.5 and history of a clinical fracture,
62%; p=0.025).
The oral 150-mg dose of monthly ibandronate has been
evaluated in the Monthly Oral Ibandronate in Ladies
(MOBILE), a 2-year, multicenter, double-blind, noninfer-
iority bridging study comparing the efficacy and safety of
once-monthly ibandronate with daily ibandronate in 1,609
postmenopausal women [70]. The 150-mg once-monthly
dose of ibandronate consistently produced greater sCTX
suppression and greater increase in lumbar and total hip
BMD (p<0.05) than the daily regimen, but the cumulative
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tolerated as daily treatment. These results were confirmed
in the MOBILE 3-year extension study [71].
The Dosing Intravenous Administration trial (DIVA)
trial is a randomized, double-blind, double dummy, non-
inferiority, international multicenter trial comparing daily
2.5 mg oral ibandronate and intermittent intravenous
ibandronate, given 2 mg every 2 months or 3 mg every
3 months, in 1,395 postmenopausal women [72]. All
patients had osteoporosis (lumbar spine T-score<−2.5).
The primary end point was change from baseline in lumbar
spine BMD at 1 year. At 1 year, mean lumbar spine BMD
increases were 5.1%, 4.8%, and 3.8% in the intravenous
2 mg, the intravenous 3 mg, and the oral daily 2.5 mg
groups, respectively. Both of the intravenous regimens not
only were noninferior but also were superior (p<0.001) to
the oral regimen. Hip BMD increases were also signifi-
cantly greater in both intravenous groups. After 1 year, the
median reduction from baseline in the sCTX level was
similar in the three treatment groups.
The ibandronate dose response for the prevention of
nonvertebral fractures has been evaluated in a pooled
analysis of individual patient data from eight randomized
trials [73]. This study was conducted to assess the effect of
high vs. lower doses of ibandronate on nonvertebral fractures
based on annual cumulative exposure (ACE). ACE was
defined as the total annual dose of bisphosphonate absorbed
and therefore available to the bone tissue taking into account
the fact that 100% of an intravenous bisphosphonate and 0.6%
of an oral dose are absorbed. The results were adjusted for
clinical fracture, age, and bone density. High ACE doses
defined as ≥10.8 mg (150 mg once monthly, 3 mg i.v. every
3m o n t h s ,a n d2m gi . v .e v e r y2m o n t h s )w e r ec o m p a r e dt o
ACE doses ≤7.2mg(100mgoralmonthly,50/50mgmonthly,
and 2.5 mg oral daily) and to low 5.5 mg ACE dose (oral
2.5 mg daily). A dose–response effect on nonvertebral
fractures was observed when comparing high with low ACE
doses. The comparison resulted in a 0.62 RR (95% CI, 0.396–
0.974; p=0.038) for ACE doses ≥10.8 mg vs. to 5.5 mg ACE
doses and in a 0.64 RR (95% CI, 0.43–0.94) for ≥10.8 mg
ACE doses vs. ≤7.2 mg ACE doses, leading to the conclusion
that higher ibandronate dose levels (150 mg monthly or 3 mg
i.v. quarterly) significantly reduced nonvertebral fracture risk
in postmenopausal women.
In a similar analysis, Harris et al. compared reduction in
fracture risk for high (≥10.8 mg), mid (7.2–5.5 mg), and low
(≤4.0 mg) ACE relative to placebo [74]. It was observed that
doses of ibandronate resulting in ACEs ≥10.8 mg, including
the marketed oral 150 mg monthly and i.v. 3 mg thrice
monthly, significantly reduce the risk of all clinical,
vertebral, and nonvertebral fractures with a 0.712 RR (95%
CI, 0.55–0.92; p=0.01). The risk of nonvertebral fractures
was also significantly reduced with a 0.701 RR (95% CI,
0.50–0.99; p=0.04). Data from the four phase III clinical
trials of ibandronate (8,710 patients) were pooled in a meta-
analysis to assess the relationship between ibandronate dose,
BMD changes, and rates of both clinical and nonvertebral
fractures [75]. It was observed that both lumbar spine and
total hip BMD increased with increasing ibandronate dose. A
statistically significant inverse linear relationship has been
reported between percent change in lumbar spine BMD and
t h er a t eo fc l i n i c a lf r a c t u r e s( p=0.005).
There is no evidence, from placebo-controlled trials, for a
reduction of nonvertebral fracture with ibandronate, but data
from the MOBILE bridging study, from meta-analysis and
from ACE evaluations, suggest a significant effect of the
marketed oral 150 and the 3 mg i.v. ibandronate on the risk
reduction of nonvertebral fractures. Hip, nonvertebral, or
clinical fracture rates were not statistically different between
patients receiving monthly oral ibandronate, weekly oral
alendronate, or risedronate in a 12-month observational study,
but patientson oralibandronate had a significantly64% lower
risk of vertebral fractures than patients on weekly bisphosph-
onates (RR, 0.36; 95% CI, 0.18–0.75; p=0.006) [76].
Both oral 2.5 mg daily and intermittent oral ibandronate
dosage (20 mg every other day for 12 doses every 3 months)
were well tolerated with an incidence of adverse events
similar to placebo in the BONE trial [69]. Once-monthly
oral ibandronate was well tolerated, with a similar safety
profile to placebo in a 3-month, double-blind, placebo-
controlled, phase I study (Monthly Oral Pilot Study) [77]
and with a similar incidence of adverse events across
groups (oral 50+50, 100, and 150 mg) in the MOBILE
study [70]. The incidence of upper gastrointestinal adverse
events was similar for the once-weekly 70-mg alendronate
and the once-monthly 150-mg ibandronate in a 12-month
comparative study [78]. After 1 year, the incidence of
proportion of patients all adverse events, treatment-related
adverse events, and treatment-related adverse events that
led to withdrawal was similar for the i.v. 2-mg twice
monthly, 3-mg thrice monthly, and oral 2.5-mg ibandronate
in the DIVA trial [72]. Renal safety has been confirmed,
without clinically relevant changes in serum creatinine,
creatinine clearance, or microalbuminuria, in patients with
breast cancer and bone metastases receiving ibandronate
6 mg every 3–4 weeks for 6 months given over 15 min [79]
or for 2 years given every 3–4 weeks over 1–2h[ 80].
To date, oral alendronate, risedronate, and ibandronate
have not been studied in head-to-head comparative trials with
fracture endpoints. Because of evidence that differences exist
in the BMD–fracture risk relationship between different
agents and that the relationship between fracture risk
reductions and BMD is not a simple linear one [77, 81],
BMD endpoint trials cannot substitute for fracture endpoint
trials and do not allow a formal comparison of the magnitude
of the treatment effects of different osteoporosis agents.
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for parenteral osteoporosis treatment. It has the highest
affinity among bisphosphonates for bone surfaces, the
maximum inhibition potency to inhibit the activity of the
farnesyl diphosphate synthesis, and the highest antiresorptive
activity [82]. One intravenous dose of ZA (4 to 20 µg/kg)
attenuated trabecular and cortical bone loss for 32 weeks in
ovariectomized rats. At 100 µg/kg, bone loss was com-
pletely suppressed. ZA was ten times more potent than
alendronate in this model [83]. The increase of bone
resorption postovariectomy, measured by TRAP5b, was
suppressed until the 32nd week, even for the lowest dose
of ZA (0.8 µg/kg). In human, one intravenous injection of
ZA decreased bone turnover for at least 1 year [84], and
perhaps even for 2 years [85], opening the road for a yearly
treatment in osteoporosis. A once-yearly intravenous injec-
tion of ZA was tested in two controlled studies. In the
Health Outcome and Reduced Incidence with Zoledronic
Acid Once Yearly Pivotal Fracture Trial (HORIZON PFT), a
yearly injection of ZA (5 mg over 15 min) given at 0, 12,
and 24 months was compared to a placebo infusion in more
than 7,500 postmenopausal women with osteoporosis who
were followed up for 3 years. All patients received daily
calcium and vitamin D supplements (1,000–1,500 mg/400–
1,200 IU). The markers of bone turnover were decreased by
30% to 59% at 12 months. BMD increased significantly (p<
0.001) at the femoral neck (5.06%; 95% CI, 4.76 to 6.28),
total hip (6.02%; 95% CI, 5.77 to 6.28), and lumbar spine
(6.71%; 95% CI, 5.69 to 7.74). The 3-year risk of
morphometric vertebral fracture was reduced by 70% (RR,
0.30; 95% CI, 0.24–0.38) and that of hip fracture by 41%
(RR, 0.59; 95% CI, 0.42–0.83). Nonvertebral fractures were
decreased by 25% (RR, 0.75; 95% CI, 0.64–0387). Clinical
vertebral fractures were reduced by 77% (RR, 0.23; 95% CI,
0.14–0.37), and all clinical fractures were reduced by 33%
(RR, 0.67; CI, 0.58–0.77; p<0.001) [86]. A subgroup of
around 150 patients included in the HORIZON trial had a
bone biopsy at the end of the observation period [87]. The
microCT and histological analysis showed the expected
reduction of the activation frequency and increased length of
the remodeling cycle, an increased trabecular bone volume
and trabecular number, and a decreased trabecular separa-
tion. There was no alteration of osteoblast function, and
even a significant increase of mineral apposition rate.
In a second study including more than 2,100 patients
(HORIZON Recurrent Fracture Trial), men and women
over 50 years old received ZA or a placebo infusion within
90 days after repair of a hip fracture. In this only trial
conducted to study the risk of fracture in patients with a
prevalent hip fracture, not only was the risk of a new
clinical fracture reduced by 35% (RR, 0.65; 95% CI, 0.50–
0.84; p<0.001) in the ZA group during the 1.9 years
follow-up but the risk of death was also reduced by 28%
(RR, 0.72; 95% CI, 0.56–0.93) in this arm [88]. A
significant reduction of fracture risk was already observed
at 12 months. The decreased mortality is only partly
explained by the reduction of fracture rates [89].
In these twocontrolled studies, theprofile was safe, witha
number of serious adverse events or deaths not significantly
different in the groups treated with ZA or with placebo. The
main problem with ZA was the postinfusion syndrome,
which is classical with all intravenous bisphosphonates
following the first infusion, usually mild, and can be reduced
by acetaminophen [90]. Intriguingly, an unexpected number
of episodes of atrial fibrillation described as severe adverse
events occurred in the ZA-treated group. The fact that the
total incidence of atrial fibrillation was not increased, that
the episodes occurred late after the injection, and that an
increased frequency of AF was not found in the
HORIZON-RFT trial suggests that this occurred by chance
[82, 91]. A recent meta-analysis provided no evidence for
an excess risk of atrial fibrillation in patients treated with
bisphosphonates [91]. This study did not reveal any
increase in the risk of stroke or cardiovascular mortality.
Asymptomatic hypocalcaemia occurred in a few patients
treated with ZA, most frequently 9 to 11 days after the
infusion. Serum creatinine increased transiently in some
patients of the ZA group. However, in the long term, there
was no alteration of the renal function [92].
Adherence to treatment is crucial to reach high-level
efficiency and low level of side effects. In clinical practice,
adherence is poor in osteoporotic patients. It has been
measured that approximately 75% of women who initiate
osteoporosis drug therapy are nonadherent within
12 months, almost 50% having discontinued their therapy
by this time [93]. This is not only observed in asymptom-
atic osteoporotic patients but also after such a severe event
as a hip fracture. Prescription rate and compliance with
bisphosphonates or SERMs after hip fracture have been
measured in 23,146 patients who had sustained a hip
fracture. Of these patients, 6% received treatment during
the study period (4.6% alendronate, 0.7% risedronate, and
0.7% RAL). At 12 months, the rate of persistence was 41%,
and the median duration of persistence was 40.3 weeks
[94]. An important factor is the frequency of drug
administration. Medication persistence has been compared
for patients receiving weekly oral or daily oral bisphos-
phonates in a large, longitudinal cohort of female patients
(n=211,319) receiving prescriptions for alendronate or
risedronate from approximately 14,000 US retail pharma-
cies. Only 56.7% of patients receiving the weekly regimen
and only 39.0% of patients receiving the daily regimen
continued to take bisphosphonate therapy at month12 of the
study period (p<0.0001) [95].
A recent study, based on an analysis of the French
national prescription database, evaluate whether monthly
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weekly treatment. Both compliance (medication possession
ratio (MPR)) and persistence (time to discontinuation) were
superior in the monthly ibandronate treatment group.
Twelve-month persistence rates were 47.5% for monthly
ibandronate and 30.4% for weekly bisphosphonates. Compli-
ance was significantly higher in the monthly cohort (MPR=
84.5%) than in the weekly cohort (MPR=79.4%). After
adjustment for potential confounding variables, women with
monthly regimens were 37% less likely to be nonpersistent
(RR=0.63 (0.56–0.72)) and presented a 5% higher mean
MPR (84.5% vs. 79.3%, p<0.001) than women with weekly
regimens [96]. Besides avoidance of the gastrointestinal side
effects, an advantage which could be expected from
intravenous administration is an improved adherence.
Osteonecrosis of the jaw (ONJ) is frequently presented
as a “classical complication” of bisphosphonate treatment,
thereby generating anxiety in osteoporotic patients and
interrogations in practitioners dealing with osteoporotic
treatment. According to a recent systematic review of the
literature for relevant studies on bisphosphonates-associated
ONJ in oncology and treated osteoporotic patients, it
appears that ONJ is rare in osteoporotic patients, with an
estimated incidence <1 case per 100,000 person-years of
exposure [97]. At the opposite, in oncology patients
receiving high-dose intravenous bisphosphonates, ONJ
appears to be dependent of the dose and duration of
therapy, with an estimated incidence of 1–12% at
36 months. The authors underline that ONJ incidence in
the general population is unknown. To date, pathogenesis
of bisphosphonate-related ONJ remains an enigma [98].
Unusual mid-shaft long bone fractures have been
reported in some patients receiving bisphosphonates,
mainly alendronate, for the treatment of osteoporosis [99–
102]. It has been hypothesized that this could be due to
prolonged suppression of bone turnover, leading to accu-
mulation of microdamage and development of hyperminer-
alized bone, but this remains to be confirmed. Two recent
histologic studies did not show indeed an increased
prevalence of microcracks in patients who had received
alendronate for more than 5 years [103, 104], though it
appears in the study by Stepan et al. that cracks become
significantly more prevalent in the alendronate-treated
patients with the lowest bone mineral densities. A recently
published epidemiological study also suggests that these
fractures are more linked to osteoporosis itself than to
bisphosphonate treatment [105]: this registered-based co-
hort study has shown that the distribution of these atypical
fractures was identical in an alendronate-treated cohort and
in an untreated cohort, and that in a small number of
patients who remained on alendronate for more than 6 years,
there was no shift from typical to atypical femur fractures,
which is reassuring. Further investigation is mandatory to
precise the usefulness of stopping bisphosphonate (after 5
or 10 years of treatment?) or monitoring bone markers to
avoid oversuppression of bone turnover.
Anabolic agents
The pharmacologic armamentarium available to clinicians to
reduce fracture risk in women with postmenopausal osteopo-
rosis consists essentially of antiresorptive agents, i.e., drugs
acting through inhibition of osteoclastic bone resorption and
lowering of global bone turnover. The only exceptions are
peptides from the PTH famil y ,w h i c h ,u n d e rs p e c i f i c
modalities of administration, act as anabolic agents stimulat-
ing bone formation, and strontium ranelate, which acts as an
uncoupling agent effecting a stimulation of bone formation
with reduction of bone resorption. The interest generated by
these alternatives to antiresorptive treatment resides in their
greaterpotentialforrestorationofbonemassandpossiblyalso
bone structure in osteoporotic subjects who have already
suffered substantial skeletal deterioration.
Peptides of the PTH family have been investigated in the
management of osteoporosis since more than 30 years
[106]. Their proposed use in the treatment of osteoporosis
is based on the observation that intermittent exposure to
low dose PTH is anabolic to the bone, in contrast to the
catabolic effects on cortical bone resulting from continuous
exposure to supraphysiological levels of PTH from either
endogenous or exogenous origin. The anabolic effects of
PTH are exerted through stimulation on the cells of
osteoblastic lineage of the PTH-1 receptor, which is shared
by both PTH and PTH-related peptide (PTHrP) and is
therefore also known as the PTH–PTHrP receptor. For
either molecules, it is the N-aminoterminal region that
activates the receptor as is more in particular the case for
PTH (1–34) also known as teriparatide. The anabolic
actions of the intermittently administered peptides from
the PTH family involve augmentation of the number of
osteoblasts through stimulation of cell replication and
inhibition of osteoblast apoptosis, and probably also
stimulation of osteoblast activity. The molecular mecha-
nisms underlying these anabolic effects are still poorly
understood, but appear to include both direct actions on
osteoblastic cells as well as indirect effects such as through
stimulation of IGF-1 production and downregulation of
sclerostin, a physiologic antagonist of the important
anabolic Wnt-β-catenin pathway. The anabolic effects of
PTH and related peptides appear to be more pronounced on
cancellous than on cortical bone [107].
The efficacy and safety of self-administered daily
subcutaneous injections of 20 µg teriparatide, the dosing
regimen presently proposed for clinical use in postmeno-
pausal osteoporosis, has been evaluated in an RCT
Osteoporos Int (2010) 21:1657–1680 1667involving 1,637 postmenopausal women with prior verte-
bral fracture (mean T-score, −2.6 at the lumbar spine),
assigned to receive daily s.c. injections of 20 or 40 µg of
teriparatide or placebo. Vertebral radiographs were obtained
at baseline and at the end of the study (median duration of
observation, 21 months), and serial measurements of bone
mass by dual energy X-ray absorptiometry (DXA) were
performed. New vertebral fractures occurred in 14% of the
women in the placebo group and in 5% of the women in the
20-µg teriparatide group. The RR of fracture as compared
with the placebo group was 0.35 (95% CI, 0.22–0.55). New
nonvertebral fragility fractures occurred in 6% of the
women in the placebo group and in 3% of the women in
the 20-µg teriparatide group (RR, 0.47; 95% CI, 0.25–
0.88). Over the 21-month observation period, compared to
placebo, the 20-µg teriparatide group increased BMD by 9
and 3 percentage points in the lumbar spine and femoral
neck, respectively. At the shaft of the radius, BMD
decreased by 2.1±4.2% in the 20-µg teriparatide group as
compared to a decrease by 1.3±3.3% in the placebo group
(p=0.09). Total body bone mineral content increased by 2
to 3 percentage points in the 20-µg teriparatide group as
compared to placebo as measured on Hologic or Lunar
DXA equipment, respectively. Nine percent of the women
in the 20-µg teriparatide group reported dizziness, and 3%
reported leg cramps, as compared to 6% and 1% of the
women in the placebo group, respectively (p=0.05 and p=
0.02, respectively); the frequency of these complaints was
not higher than in the placebo group for the higher
teriparatide dosage. A limited increase of the report of
nausea and headache in the higher teriparatide dose group
was not different from placebo in the 20-µg teriparatide
group. Mild hypercalcemia (defined as a calcium concen-
tration that exceeded 10.6 mg/dl) occurred at least once in
11% of the patients treated with 20 µg teriparatide daily
(95% were less than 11.2 mg/dl) as compared to 2%
hypercalcemia in the women in the placebo group; 3% of
the women on the 20-µg teriparatide treatment required
dose reduction because of persistent hypercalcemia, and
treatment had to be discontinued in a single patient.
Treatment resulted in a limited increase of calciuria without
increase of the prevalence of hypercalciuria. Compared to
the 20-µg teriparatide treatment, a treatment with a higher
daily dose of 40 µg teriparatide resulted in a larger increase
of BMD at the lumbar spine and the femoral neck, a larger
decrease of BMD at the shaft of the radius, a similar
reduction in the risk of vertebral and nonvertebral fracture,
and a higher incidence of hypercalcemia [108, 109].
In contrast with the effects of antiresorptive drugs on
biochemical markers ofboneturnover,the treatmenteffects of
teriparatide on BMD and fracture risk reduction are underlied
bymarkedandsustainedincreases inthe biochemicalmarkers
of bone turnover, an initial rapid and marked increase of the
markers of bone formation being followed with a delay of
about 1 month by a less pronounced increase of the markers
of bone resorption [110]. The magnitude of early changes in
markers of bone formation has been shown to correlate with
increases of BMD at 18 months of treatment [111] and with
improvements in bone structure as shown by histomorph-
ometry and including augmentation of cancellous bone with
increased trabecular thickness and connectivity [112]. The
antifracture efficacy of teriparatide on spinal fracture does
not seem to be modulated by age of the subjects (<65, 65–75,
or>75years),prevalentspinalBMDvalues(T-score<−2.5or
>−2.5), or the number of prevalent fractures (one or two or
more fractures) [113], and the response to treatment does not
appear different in postmenopausal patients with baseline 25
(OH)D insufficiency (serum 25(OH)D >10 but ≤75 nmol/
ml) or sufficiency (>75 nmol/ml) [114].
At the end of the randomized placebo controlled trial
having demonstrated the efficacy of 20 µg daily subcuta-
neous injections of teriparatide in postmenopausal osteopo-
rosis [108], the patients were followed for an additional
18-month period without teriparatide, during which they
w e r ea l l o w e dt ou s ea n ya n t iosteoporotic medication
considered appropriate by their treating physician. While
the proportion of patients having received an inhibitor of
bone resorption was slightly higher in patients previously in
the placebo group than in the patients having been treated
with 20 µg/day teriparatide, the reduction of vertebral
fractures observed in this particular group during the initial
trial was confirmed during this 18-month follow-up
observation period (RR, 0.59; 95% CI, 0.42–0.85) [115].
Since the efficacy and safety of teriparatide in postmeno-
pausal osteoporosis has been studied for a mean duration of
only 21 months of active treatment, this compound has
been released for clinical use for treatments of limited
duration, set at 18 and 24 months according to the
European and US regulatory agencies, respectively. More-
over, treatment duration tend to be also limited by the
relatively high cost of treatment. However, interruption of
treatment is followed by a rapid decrease of BMD, which
can be prevented by subsequent treatment with a biphosph-
onate [115]. Furthermore, from theoretical considerations, it
had been proposed that concomitant treatment of teriparatide
with an antiresorptive agent mightpossibly allowfor improved
therapeutic efficacy, compared to teriparatide alone, consider-
ingthedifferentmechanismsofaction.Forthesereasons,there
has been considerable interest for combination therapies
combining teriparatide with an antiresorptive agent adminis-
tered either concomitantly or consecutively. Available data on
biochemical markers of bone turnover and BMD indicate that
concomitant treatment of teriparatide with a strong antiresorp-
tive drug, such as alendronate, does not result in a synergestic
effect with the biphosphonate rather mitigating the effect of
teriparatide [116]. In a trial of only 6 months duration,
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drug RAL did result in greater gain of BMD at the hip [117].
Taken the rapid bone loss after cessation of treatment,
subsequent treatment with an antiresorptive agent seems
advisable to preserve the gains achieved during teriparatide
treatment. On the other hand, patients who are candidate for
treatment with teriparatide have not uncommonly previously
been treated with an antiresorptive agent. In fact, in Belgium,
as well as in some other countries, failure of treatment with an
antiresorptive drug is a condition for reimbursement of
treatment with teriparatide. The available data suggest that
prior treatment with antiresorptive drugs does not compromise
the ultimate treatment effects of teriparatide, although the
treatment effects may be initially blunted in women previously
treated with some antiresorptive agents [107, 118].
Anabolic effects in postmenopausal osteoporosis with
stimulation of bone turnover and increases of BMD have
also been documented for PTH (1–84) [119, 120].
However, documentation of antifracture efficacy is limited
to vertebral fractures and with some methodological
reservations, whereas the rate of adverse events was rather
high [120]. The efficacy and safety of 18 months daily s.c.
injections of 100 µg human recombinant (1–84) PTH was
assessed in an RCT in postmenopausal osteoporosis [120].
Women with low BMD (mean lumbar spine T-score around
−3) without or with (only 18.6%) prevalent vertebral
fracture were randomized to receive PTH (n=1,286) or
placebo (n=1,246) with daily supplemental calcium
(700 mg) and vitamin D (400 IU) in both groups. Overall
dropout was high (n= 8 3 1 )w i t ho n l y7 0 %a n d6 4 %
completing the study in the placebo and PTH group,
respectively. Moreover, at discontinuation or completion
of the study, only 66% in the PTH group as compared to
91% in the placebo group had received daily injection with
or without supplemental calcium. The RR of new or
worsened vertebral fracture in women treated with PTH
was 0.42 (95% CI, 0.24–0.72; p<0.001); this is assuming
no fracture in the women who did not complete the study.
In sensitivity analyses, the RR was 0.60 (95% CI, 0.36–1.0;
p=0.05) if the patients who prematurely discontinued had a
fracture rate similar to that in all patients completing the
trial and was 0.62 (95% CI, 0.37–1.04; p=0.07) if they had
a fracture rate similar to that in placebo recipients who
completed the trial. In this study, PTH (1–84) treatment
resulted in a rather substantial increase if the incidence of
hypercalcemia is 23% (95% CI, 21–26%) and hyper-
calciuria is 24% (95% CI, 20–27%).
Strontium ranelate
Strontium ranelate is a new treatment of postmenopausal
osteoporosis that reduces the risk of vertebral and hip
fractures. It is the first antiosteoporotic agent that appears to
simultaneously increase bone formation and decrease bone
resorption, thus uncoupling the bone remodeling process
[121]. Specifically, the dual mode of action of strontium
ranelate is due to direct effects on both osteoblasts and
osteoclasts, as reflected by the changes in bone markers in
clinical trials [122]. Several studies in various models have
demonstrated that strontium ranelate increases osteoblast
replication, differentiation, and activity [123], while in
parallel, it downregulates osteoclast differentiation and
activity [124–126]. A recent study has shown that strontium
ranelate increases the expression of the bone-specific alkaline
phosphatase (bALP;osteoblastdifferentiation)andthenumber
of the bone nodules (osteoblast activity) of murine osteoblasts.
In parallel, strontium ranelate decreases the tartrate resistant
acid phosphatase activity (osteoclast differentiation) and the
capability of murine osteoclasts to resorb (osteoclast activity),
probably by acting on the cytoskeleton of these cells [127]. In
addition to these direct effects on osteoblasts and osteoclasts,
strontium ranelate also modulates the level of osteoprotegerin
(OPG) and RANKL, two molecules strongly involved in the
regulation of osteoclastogenesis by osteoblasts. Other studies
have demonstrated the involvement of the calcium-sensing
receptor in the effects of strontium ranelate on osteoblasts,
osteoclasts, and OPG/RANKL regulation [126]. Finally,
strontium ranelate administration decreased bone resorption
and maintained bone formation in adult ovariectomized rats,
which resulted in prevention of bone loss, an increase in bone
strength, and a positive effect on intrinsic bone properties
[128]. It should be kept in mind, however, that strontium
ranelate reduces resorption andstimulates formation to a lesser
extent than bisphosphonates and teriparatide, respectively
[127].
Strontium ranelate has been investigated in a large phase
3 program, initiated in 1996, which includes two extensive
clinical trials for the treatment of established osteoporosis
[122, 129, 130]. The Spinal Osteoporosis Therapeutic
Intervention (SOTI) study was aimed at assessing the effect
of strontium ranelate on the risk of vertebral fractures [122].
The Treatment of Peripheral Osteoporosis (TROPOS) trial
aimed to evaluate the effect of strontium ranelate on
peripheral (nonspinal) fractures [129]. Both studies were
multinational, randomized, double-blind, and placebo-
controlled, with two parallel groups (strontium ranelate
2 g/day, taken orally 2 h apart from the meals vs. placebo)
[122, 129]. The study duration was 5 years, with main
statistical analysis planned after 3 years of follow-up. One
thousand six hundred forty-nine patients were included in
SOTI (mean age 70 years), and 5,091 patients were
included in TROPOS (mean age 77 years) [130].
The primary analysis of SOTI [122] (ITT, n=1,442),
evaluating the effect of strontium ranelate 2 g/day on
vertebral fracture rates, revealed a 41% reduction in RR of
Osteoporos Int (2010) 21:1657–1680 1669experiencing a new vertebral fracture (semiquantitative
assessment) with strontium ranelate throughout the 3-year
study compared with placebo (139 patients with vertebral
fracture vs. 222, respectively (RR, 0.59; 95% CI, 0.48–
0.73; p<0.001). The RR of experiencing a new vertebral
fracture was significantly reduced in the strontium ranelate
group as compared with the placebo group for the first year.
Over the first 12 months, RR reduction was 49% (RR, 0.51;
95% CI, 0.36–0.74; Cox model p<0.001).
The primary analysis of TROPOS (ITT, n=4,932),
evaluating the effect of strontium ranelate 2 g/day on
nonvertebral fracture, showed a 16% RR reduction in all
nonvertebral fractures over a 3-year follow-up period (RR,
0.84; 95% CI, 0.702–0.995; p=0.04) [129]. Strontium
ranelate treatment was associated with a 19% reduction in
risk of major nonvertebral osteoporotic fractures (RR, 0.81;
95% CI, 0.66–0.98; p=0.031). In the high-risk fracture
subgroup (n=1,977; women; mean age≥74 years; femoral-
neck BMD T-score of less than or equal to −2.4 according
to National Health and Nutrition Examination Survey
normative value), treatment was associated, in a post hoc
analysis requested by the European regulatory authorities,
with a 36% reduction in risk of hip fracture (RR, 0.64; 95%
CI, 0.412–0.997; p=0.046).
Of the 5,091 patients, 2,714 (53%) completed the study up
to 5 years [130]. The risk of nonvertebralfracture was reduced
by 15% in the strontium ranelate group compared with the
placebo group (RR, 0.85; 95% CI, 0.73–0.99). The risk of hip
fracturewasdecreasedby43%(RR,0.57;95%CI,0.33–0.97),
and the risk of vertebral fracture was decreased by 24% (RR,
0.76;95%CI,0.65–0.88)inthestrontiumranelategroup.After
5 years, the safety profile of strontium ranelate remained
unchanged compared with the 3-year findings [131].
In addition, the very long-term efficacy of strontium
ranelate has been investigated in an extension of the SOTI
and TROPOS studies, in which a total of 879 patients were
entered into a 3-year open-label extension to examine the
impact of administration over 8 years [132]. The cumulative
incidence of vertebral fractures over the extension was
13.7%, compared with 11.5% in the combined original trials,
while the cumulative incidence of nonvertebral fractures over
the TROPOS extension was 12.0%, compared with 9.6% in
the first 3 years of the study [132]. Despite an increased
fracture risk with aging, there was no significant difference
in vertebral and nonvertebral fracture risk between the
original trial periods and the open-label extensions suggest-
ing the maintenance of antifracture efficacy of this agent
[132]. There were no additional safety concerns [132].
In order to assess the efficacy of strontium ranelate
according to the main determinants of vertebral fracture risk
(age, baseline BMD, prevalent fractures, family history of
osteoporosis, baseline body mass index, and addiction to
smoking), data from SOTI and TROPOS (n=5,082) were
pooled (strontium ranelate 2 g/day group (n=2,536);
placebo group (n=2,546); average age 74 years; 3-year
follow-up) [133]. This study showed that a 3-year treatment
with strontium ranelate leads to antivertebral fracture
efficacy in postmenopausal women independently of
baseline osteoporotic risk factors [133].
To determine whether strontium ranelate also reduces
fractures in elderly patients, an analysis based on pre-
planned pooling of data from the SOTI and TROPOS trials
included 1,488 women between 80 and 100 years of age
followed for 3 years [134]. In the ITT analysis, the risk of
vertebral, nonvertebral, and clinical (symptomatic vertebral
and nonvertebral) fractures was reduced within 1 year by
59% (p=0.002), 41% (p=0.027), and 37% (p=0.012),
respectively. At the end of 3 years, vertebral, nonvertebral,
and clinical fracture risks were reduced by 32% (p=0.013),
31% (p=0.011), and 22% (p=0.040), respectively. The
medication was well tolerated, and the safety profile was
similar to that in younger patients.
Strontium ranelate was studied in 1,431 postmenopausal
women, from the SOTI and TROPOS studies, with
osteopenia [135]. In women with lumbar spine osteopenia,
strontium ranelate decreased the risk of vertebral fracture
by 41% (RR, 0.59; 95% CI, 0.43–0.82; p=0.002), by 59%
in women with no prevalent fractures (RR, 0.41; 95% CI,
0.17–0.99; p=0.039), and by 38% in women with prevalent
fractures (RR, 0.62; 95% CI, 0.44–0.88; p=0.008). In
women with osteopenia both at the lumbar spine and the
femoral neck, strontium ranelate reduced the risk of fracture
by 52% (RR, 0.48; 95% CI, 0.24–0.96; p=0.034).
After 3 years of strontium ranelate 2 g/day, each
percentage point increase, without correction for SR
adsorption to hydroxyapatite crystals, in femoral neck,
and total proximal femur BMD was associated with a 3%
(95% adjusted CI, 1–5%) and 2% (1–4%) reduction in risk
of new vertebral fracture, respectively. The 3-year changes
in femoral neck and total proximal femur BMD explained
76% and 74% of the reduction in vertebral fractures
observed during the treatment, respectively [135, 136].
In the SOTI and TROPOS trials, the incidence of
adverse events, serious adverse events, and withdrawals
due to adverse events was similar in the strontium ranelate
and placebo groups [137, 138]. During the first 3 months of
treatment, nausea, diarrhea, headache, dermatitis, and
eczema were more frequently associated with strontium
ranelate compared to placebo, but, thereafter, there was no
difference in incidence between strontium ranelate and
placebo groups concerning nausea and diarrhea.
In pooled data from the SOTI and TROPOS trials, there
was an apparent increased risk of venous thromboembolism
in the strontium ranelate group (0.6% vs. 0.9% per year),
although the annual incidence was similar in the strontium
ranelate and placebo groups in the individual trials [122,
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Practice Research Database to assess the risk of several
recently reported adverse eventslinked to the use ofstrontium
ranelate for osteoporosis in postmenopausal women [139].
Age-adjusted rate ratios for venous thromboembolism, gas-
trointestinal disturbance, minor skin complaint, and memory
loss were 1.1 (95% CI, 0.2–5.0), 3.0 (95% CI, 2.3–3.8), 2.0
(95% CI, 1.3–3.1), and 1.8 (95% CI, 0.2–14.1), respectively.
No cases of ONJ, Stevens–Johnson syndrome, or drug rash
with eosinophilia and systemic symptoms were found.
Recently, the postmarketing experience of patients
treated with strontium ranelate reported cases of the drug
reaction with eosinophilia and systemic symptoms
(DRESS) syndrome (<20 for 570,000 patient-years of
exposure) [138]. This incidence is in the vicinity of what
has been previously reported as severe skin reactions, with
most of the other currently marketed antiosteoporosis
medications. A causative link has not been firmly estab-
lished, as strontium is a trace element naturally present in
the human body, and ranelic acid is poorly absorbed. Due
to the possible fatality linked to this syndrome, however, it
seems reasonable to discontinue immediately strontium
ranelate and other concomitant treatment known to induce
such a syndrome in case of suspicious major skin disorders
occurring within 2 months of treatment initiation [140] and
to introduce adapted treatment and follow-up to avoid
systemic symptoms. Anecdotic cases of alopecia were also
reported, but no causative link was formally established
[141]. Strontium ranelate is not indicated in patients with
severe kidney failure (i.e., with creatinine clearance below
30 ml/min).
New therapeutic perspectives
Blockade of the RANK—RANK ligand (RANKL) pathway
The discovery of the OPG—RANK ligand (RANKL)—
RANK system has allowed unraveling the mechanisms
whereby osteoblastic cells regulate bone resorption. The
most critical molecules for the differentiation, activation,
and survival of osteoclasts are indeed the receptor activator
of nuclear factor NF-κB (RANK), its ligand RANKL, a
member of the tumor necrosis factor (TNF) superfamily,
and OPG that acts as a decoy receptor for RANKL.
RANKL and OPG are principally produced by osteoblasts
and marrow stromal cells [142, 143]. OPG competitively
inhibits the binding of RANKL to RANK on osteoclasts
and their precursors. This results in inhibition of the fusion
of osteoclast precursor cells, blockade of the activation of
mature osteoclasts, and induction of osteoclast apoptosis.
OPG is a powerful inhibitor of bone resorption that could
have been used clinically [144, 145]. However, because
OPG also binds to the cytotoxic ligand TRAIL and other
members of the TNF family, a specific fully human
antibody against RANKL has been developed (Amgen).
This antibody, named denosumab, has been shown to
specifically bind to RANKL with a very high affinity,
preventing its interaction with the receptor RANK. More-
over, animal studies showed that this antibody had
pharmacokinetic and pharmacodynamic advantages as
compared to an OPG construct. Denosumab has a very
long circulating half-life (1–1.5 months), and administra-
tion of a single dose by the subcutaneous route induces a
rapid (12 h), marked (decrease in uNTX >80%) and
prolonged (>6 months) inhibition of bone resorption in
postmenopausal women [146]. The interest for using
denosumab to counteract postmenopausal bone loss was
enhanced by the knowledge that disequilibrium of the
balance between RANKL and OPG plays a major role in
the pathogenesis of osteoporosis. RANKL expression is
increased after menopause, whereas estrogens stimulate
OPG production [147]. RANKL expression is indeed
significantly higher in bone marrow cells isolated from
early untreated postmenopausal women than in cells
obtained from pre- or postmenopausal women treated with
estrogens [148].
A phase 2 study has been conducted in 412 postmeno-
pausal women with low bone mass. Various therapeutic
schedules of denosumab were tested against placebo and
against alendronate as a positive control. After 1 and
2 years, BMD changes with denosumab 30 mg every
3 months and >60 mg every 6 months were similar to, or in
some cases greater than, the changes obtained with
alendronate. Denosumab tended to produce greater bone
density increments than alendronate at skeletal sites
enriched for cortical bone. The drug was well tolerated.
The only concern was the occurrence of six cases (in 314
patients) of infections associated with hospitalizations [149,
150]. This concern was not confirmed in a phase III study
where there were no significant differences between
denosumab and placebo in prespecified adverse events,
including infections [151]. The antifracture efficacy of
denosumab has been evaluated in a placebo-controlled
phase 3 trial including 7,868 postmenopausal osteoporotic
women who received 60 mg denosumab every 6 months or
matching placebo for a total of 3 years (the FREEDOM
trial). Both groups of patients also received 1 g of calcium
and 400–800 IU of vitamin D; 83% of the population
completed the study. The primary endpoint was the
occurrence of new vertebral fractures. There was a 68%
(95% CI, 59–74%) reduction in the incidence of new
vertebral fractures (7.2% in the placebo group vs. 2.3% in
the denosumab group). The incidence of clinical vertebral
fractures was similarly reduced by 69% (95% CI, 53–80%).
The incidence of nonvertebral fractures was reduced by
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number 69) by 40% (95% CI, 3–63%). As determined in a
substudy including 441 patients, lumbar spine BMD
increased by 9.2% at 3 years and total hip BMD by 6%
compared to placebo, whereas serum CTX decreased by
72% compared to placebo [151].
The effects of denosumab and alendronate on BMD and
biochemical markers of bone turnover have been compared
in a randomized, blinded, phase 3 trial. One thousand one
hundred eighty-nine postmenopausal women with a T-score
<−2.0 at the lumbar spine or total hip were randomized 1:1
between s.c. denosumab 60 mg every 6 months plus oral
placebo weekly or oral alendronate 70 mg weekly plus s.c.
placebo injections every 6 months for 1 year. There were
larger gains in BMD at all measured skeletal sites (lumbar
spine, total hip, femoral neck, trochanter, and one third
radius) in denosumab-treated patients than in alendronate-
treated patients. Thus, the least squares mean (95% CI)
treatment difference between the denosumab and alendro-
nate groups were 1.1% (0.7–1.4%) at the lumbar spine,
1.0% (0.7–1.2%) at the total hip, and 0.6% (0.3–1.0%) at
the femoral neck. Denosumab treatment also led to a
significantly greater reduction in bone turnover markers
compared with alendronate therapy. The overall safety
profile was similar for both treatments [152].
Other molecules in development
New SERMs are in different development phases, notably
lasofoxifene and arzoxifene. The Postmenopausal Evalua-
tion and Risk-reduction with Lasofoxifene placebo-
controlled trial enrolled 8,566 osteoporotic women treated
during 3 years. Compared with placebo, the 0.5-mg daily
dose significantly reduced the risk of new vertebral
fractures (RR, 0.58; 95% CI, 0.45–0.73) and of non-
vertebral fractures as well (RR, 0.78; 95% CI, 0.64–0.96).
Lasofoxifene reduced the risk of estrogen receptor positive
breast cancer (RR, 0.24; 95% CI, 0.09–0.65). There was an
increased risk of venous thromboembolism (RR, 2.40, 95%
CI, 1.21–4.74) but neither of endometrial cancer nor stroke
[153]. The full publication is awaited. Despite favorable
initial data [154], the development of arzoxifene, another
new SERM, has been stopped. Bazedoxifene is another
new SERM with beneficial effects on bone without
undesirable effects on the endometrium and breast. The
phase III study was a double-blind, randomized, placebo-
and RAL-controlled randomized 3-year multinational study
that included 6,847 osteoporotic women aged 55 years or
more (intent-to-treat population). Patients were treated with
bazedoxifene 20 or 40 mg/day, RAL 60 mg/day, or placebo.
Relative to placebo, bazedoxifene 20 and 40 mg and RAL
60 mg reduced the risk of new vertebral fractures (primary
endpoint) by 42% (RR, 0.58; 95% CI, 0.38–0.89), 37%
(RR, 0.63; 95% CI, 0.42–0.96), and 42% (RR, 0.58; 95%
CI, 0.38–0.89), respectively. The treatment effect was similar
among subjects with or without prevalent vertebral fracture.
Overall, there were no significant differences in the incidence
of nonvertebral fractures among treatment groups. In post hoc
analyses, bazedoxifene reduced the risk of nonvertebral
fractures in subjects at higher fracture risk [155].
Other potentially useful inhibitors of bone resorption
include cathepsin K inhibitors, src kinase inhibitors,
integrin inhibitors, chloride channel inhibitors, and PTHrP
antibodies. Cathepsin K inhibitors are the only ones of
these candidate drugs currently in phase 3 development.
Cathepsin K is a lysosomal protease that is highly
expressed in osteoclasts and plays a pivotal role in the
degradation of bone collagen. Cathepsin K inhibitors have
been shown in preclinical studies to reverse ovariectomy-
induced bone loss and to restore bone strength [156]. As
with src inhibitors, cathepsin K inhibitors appear to
decrease bone resorption without substantially decreasing
bone formation, which could lead to greater increases in
bone density than are observed in response to presently
available antiresorptive agents. Odanacatib is a highly
selective, nonlysosomotropic cathepsin K inhibitor, struc-
turally distinct from other inhibitors that occasionally
induced “morphea-like” skin changes. Various doses of
odanacatib, given orally once weekly, were tested against
placebo in a 2-year study in 399 previously untreated
postmenopausal women with low BMD (T-score <−2).
Odanacatib treatment resulted in dose-related increases in
BMD vs. baseline at trabecular and cortical bone sites.
Lumbar spine and total hip BMD increased by 5.5% and
3.2%, respectively [157]. The safety profile of 50 mg given
weekly appears to be similar to placebo, and the antifracture
efficacy of odanacatib 50 mg once weekly is currently
being tested in a phase 3 trial. New agents to stimulate bone
formation are also in development, among which, a human
antibody against sclerostin will soon enter phase 3 clinical
trials. Pharmacodynamic studies have shown that this
antibody can increase BMD and bone formation markers
[158].
Conclusions
During the last decade, several new therapeutic options have
emerged, characterized by the unequivocal demonstration of
their antifracture efficacy and an improved safety profile,
leading to a positive risk/benefit balance. Whereas most of
them have proven to significantly reduce the occurrence of
vertebral fractures (Table 1), some discrepancies remain
regarding the level of evidence related to their nonvertebral
or hip antifracture effect (Table 2). Based on a systematic
review and a critical appraisal of the current literature, the
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postmenopausal osteoporosis in Belgium.
& Calcium and vitamin D supplementation should be a
first-line strategy for the management of osteoporosis.
Based on the very low mean dietary intake of calcium
in the Belgian population, a systematic pharmacological
supplementation (1,000–1,200 mg of calcium ion daily)
in postmenopausal women appears to be an appropriate
strategy (unless an individual dietary assessment reveals
a satisfactory intake). The high prevalence of vitamin D
deficiency in elderly Belgian subjects, combined with
the low marginal cost of a calcium–vitamin D supple-
mentation compared with calcium alone, suggest that,
after the age of 65, calcium and (800–1,000 IU) vitamin
D should be systematically offered to all postmeno-
pausal women, either alone or, if needed, in combina-
tion with another therapeutic regimen.
& HRTcan no longer be considered as a first-line treatment
for osteoporosis. It should only be considered in women
experiencing climacteric symptoms, for the shortest
possible duration and with the lowest effective doses.
& Selective-estrogen receptor modulators are a first-line
option for women with low BMD, with or without
fractures. Their effect on vertebral fracture is unequiv-
ocal, across different degrees of skeletal fragility,
ranging from osteopenia to severe osteoporosis. Evi-
dence of antifracture efficacy against nonvertebral
fractures is limited to a post hoc analysis performed in
a high-risk subset of the population. Breast benefits
have been documented and should be taken into
account when assessing the overall risk/benefit ratio of
SERMs.
& Bisphosphonates reduce vertebral, nonvertebral, and hip
fractures in women with established osteoporosis (low
BMD and prevalent fractures). Due to their beneficial
effect on hip fractures, bisphosphonates are first-line
agents in the treatment of elderly subjects. There is
currently no compelling evidence for significant differ-
ences in the magnitude of the treatment effects between
alendronate, risedronate, ibandronate, and zoledronate
more especially as the dosage regimens usually pre-
Table 1 Effect on vertebral fracture rates (from randomized controlled
trials)
Osteopenia Osteoporosis
(without prevalent
vertebral fractures)
Established
osteoporosis
(with prevalent
vertebral fractures)
Raloxifene ●■ ■
Alendronate NA ■■
Risedronate NA ●■
Ibandronate NA ■■
Zoledronate NA ■■
Teriparatide NA NA ■
Strontium
ranelate
●■ ■
Denosumab NA ■■
NA No evidence available
■ Denotes a preplanned analysis in the entire study population
● Denotes a post hoc analysis
Table 2 Effect on nonvertebral/hip fracture rates (from randomized controlled trials)
Nonvertebral Hip
Osteoporosis (without
prevalent vertebral fractures)
Established osteoporosis
(with prevalent vertebral
fractures)
Osteoporosis (without
prevalent vertebral fractures)
Established osteoporosis
(with prevalent vertebral
fractures)
Raloxifene NA ● NA NA
Alendronate ■■ NA ■
Risedronate NA ■ NA ■
Ibandronate NA ● NA NA
Zoledronate ■ NA ■ NA
Teriparatide NA ■ NA NA
Strontium Ranelate ●■ ●▲
Denosumab ■ NA ■ NA
NA no evidence available
■ Denotes a preplanned analysis in the entire study population
▲ Denotes a preplanned analysis on a subset of the study population
● Denotes a post hoc analysis
Osteoporos Int (2010) 21:1657–1680 1673scribed for weekly and monthly oral bisphosphonates
have been indirectly adapted from bridging studies
based on BMD end points. From an evidence-based
perspective, the duration of bisphosphonate treatment
should not exceed the duration of randomized con-
trolled clinical trials having unequivocally demonstrated
a fracture reduction compared with a placebo. Concerns
have been raised that prolonged use of certain
bisphosphonates may be harmful for bone strength by
oversuppressing bone resorption, hence preventing
removal of spontaneously occurring microcracks and
inducing excessive mineralization. However, these
concerns come only from studies performed in animals,
and their relevance to human subjects remains to be
clarified.
& Teriparatide decreases vertebral and nonvertebral frac-
tures in subjects with both low bone density and
prevalent vertebral fractures. In order to optimize the
cost-benefit ratio of this drug, its use should be confined
to this high-risk population.
& Strontium ranelate reduces vertebral fractures in women
with osteopenia, osteoporosis, and severe osteoporosis.
Reduction of nonvertebral and hip fracture has been
shown, over 5 years, in elderly subjects with low
femoral density, making this drug a first-line therapy in
this population.
& Except for strontium ranelate, there is no linear
relationship between increases in BMD or reductions
in bone turnover and fracture risk reductions. Different
osteoporosis agents should not be compared on the
basis of their respective impact on surrogate endpoints
like BMD or bone turnover. The regular assessment
(yearly) of BMD is an appropriate option to follow
patients treated with bisphosphonates or strontium
ranelate. For RAL-treated patients, biochemical markers
of bone turnover, brought back to normal values for
premenopausal women, may be a better indication of
efficacy. The optimal monitoring tools for teriparatide
remain to be defined.
& Combination use of antiresorptive agents cannot be
recommended, because of the associated cost without
documented additional antifracture benefits, the in-
creased potential for side effects, and the risk of
inducing oversuppression of bone turnover. However,
if low doses of estrogen, used for the management of
climacteric symptoms, are insufficient to normalize
bone turnover, the addition of a bisphosphonate to
HRT may be considered.
& Current data discourage the concomitant use of alendr-
onate and PTH since the bisphosphonate appears to
blunt the anabolic action of PTH.
& Risk factor alterations, including fall prevention strate-
gies, are recommended.
& Denosumab significantly reduces spinal, nonvertebral,
and hip fractures in women with postmenopausal
osteoporotic women. It could be a first-line treatment,
in this particular indication, providing no safety
concerns emerge after longer follow-up and more
extensive use.
Conflicts of interest Jean-Yves Reginster on behalf of the Depart-
ment of Public Health, Epidemiology and Health Economics of the
University of Liège, Liège, Belgium.
Consulting fees or paid advisory boards: Servier, Novartis, Negma,
Lilly, Wyeth, Amgen, GlaxoSmithKline, Roche, Merckle, Nycomed,
NPS, and Theramex.
Lecture fees when speaking at the invitation of a commercial sponsor:
Merck Sharp and Dohme, Lilly, Rottapharm, IBSA, Genevrier,
Novartis, Servier, Roche, GlaxoSmithKline, Teijin, Teva, Ebewee
Pharma, Zodiac, Analis, Theramex, Nycomed, and Novo-Nordisk.
Grant support from industry: Bristol Myers Squibb, Merck Sharp &
Dohme, Rottapharm, Teva, Lilly, Novartis, Roche, GlaxoSmithKline,
Amgen, and Servier.
Jean-Jacques Body has received speakers and consultant fees from
Amgen and Novartis, and research support from Merck Sharp &
Dohme, Novartis, Procter & Gamble, Servier, and Roche.
Yves Boutsen has received speakers and/or consultant fees and/or
research support from Procter & Gamble, Eli-Lilly, Daiichi-Sankyo,
Merck Sharp & Dohme, Novartis, Servier, and Roche.
Jean-Marc Kaufman has received speakers and/or consultant fees and/
or research support from Amgen, Daiichi-Sankyo, Glaxo Smith Kline,
Meck Sharp & Dohme, Novartis, Nycomed, Servier, and Roche.
Stephan Goemaere has received speakers fees and/or research support
from Amgen, Eli Lilly, Glaxo Smith Kline, Merck Sharp & Dohme,
Novartis, Nycomed, Proctor & Gamble, Sanofi-Aventis, Servier, and
Roche.
Steven Boonen has received consulting fees and/or research support
from Amgen, Merck, Novartis, Nycomed, Procter & Gamble
Pharmaceuticals, and Sanofi-Aventis.
Pierre Bergmann has no conflict of interest.
Jean-Pierre Devogelaer participated in most of trials with antiosteo-
porotic drugs.
Serge Rozenberg has no conflict of interest.
Open Access This article is distributed under the terms of the Creative
Commons Attribution Noncommercial License which permits any
noncommercial use, distribution, and reproduction in any medium,
provided the original author(s) and source are credited.
References
1. Cummings SR, Black DM, Rubin SM (1989) Lifetime risks of
hip, Colles', or vertebral fracture and coronary heart disease
among white postmenopausal women. Arch Intern Med
149:2445–2448
2. Autier P, Haentjens P, Bentin J, Baillon JM, Grivegnee AR,
Closon MC, Boonen S (2000) Costs induced by hip fractures: a
prospective controlled study in Belgium. Belgian Hip Fracture
Study Group Osteoporos Int 11:373–380
3. Cranney A, Tugwell P, Wells G, Guyatt G (2002) Meta-analyses
of therapies for postmenopausal osteoporosis. I. Systematic
1674 Osteoporos Int (2010) 21:1657–1680reviews of randomized trials in osteoporosis: introduction and
methodology. Endocr Rev 23:496–507
4. Kanis JA, Burlet N, Cooper C, Delmas PD, Reginster JY,
Borgstrom F, Rizzoli R (2008) European guidance for the
diagnosis and management of osteoporosis in postmenopausal
women. Osteoporos Int 19:399–428
5. Boonen S, Body JJ, Boutsen Y, Devogelaer JP, Goemaere S,
Kaufman JM, Rozenberg S, Reginster JY (2005) Evidence-based
guidelines for the treatment of postmenopausal osteoporosis: a
consensus document of the Belgian Bone Club. Osteoporos Int
16:239–254
6. Kanis JA, Burlet N, Cooper C, Delmas PD, Reginster JY,
Borgstrom F, Rizzoli R, European Society for Clinical and
Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO)
(2008) European guidance for the diagnosis and management of
osteoporosis in postmenopausal women. Osteoporos Int 19:399–
428
7. Neuprez A, Johansson H, Kanis JA, McCloskey EV, Oden A,
Bruyere O, Hiligsmann M, Devogelaer JP, Kaufman JM,
Reginster JY (2009) Rationalisation du remboursement des
médicaments de l'ostéoporose: de la mesure isolée de la densité
osseuse à l'intégration des facteurs cliniques de risque fractur-
aire. Validation de l'algorithme FRAX®. Rev Med Liege
64:612–619
8. Rizzoli R, Boonen S, Brandi ML, Burlet N, Delmas P, Reginster
JY (2008) The role of calcium and vitamin D in the management
of osteoporosis. Bone 42:246–249
9. Boonen S, Bischoff-Ferrari HA, Cooper C, Lips P, Ljunggren O,
Meunier PJ, Reginster JY (2006) Addressing the musculoskeletal
components of fracture risk with calcium and vitamin D: a
review of the evidence. Calcif Tissue Int 78:257–270
10. NIH Consensus conference (1994) Optimal calcium intake. NIH
consensus development panel on optimal calcium intake. JAMA
272:1942–1948
11. Thomas SD, Need AG, Tucker G, Slobodian P, O'Loughlin PD,
Nordin BE (2008) Suppression of parathyroid hormone and bone
resorption by calcium carbonate and calcium citrate in postmen-
opausal women. Calcif Tissue Int 83:81–84
12. Deprez X, Fardellone P (2003) Nonpharmacological prevention
of osteoporotic fractures. Joint Bone Spine 70:448–457
13. Lips P, Bouillon R, van Schoor N, Vanderschueren D, Verschueren
S, Kuchuk N, Milisen K, Boonen S (2009) Reducing fracture risk
with calcium and vitamin D. Clin Endocrinol. doi:10.1111/j.0300-
0664.2009.03701.x
14. Chapuy MC, Arlot ME, Duboeuf F, Brun J, Crouzet B, Arnaud
S, Delmas PD, Meunier PJ (1992) Vitamin D3 and calcium to
prevent hip fractures in the elderly women. N Engl J Med
327:1637–1642
15. Chapuy MC, Arlot ME, Delmas PD, Meunier PJ (1994) Effect of
calcium and cholecalciferol treatment for three years on hip
fractures in elderly women. BMJ 308:1081–1082
16. Chapuy MC, Pamphile R, Paris E, Kempf C, Schlichting M,
Arnaud S, Garnero P, Meunier PJ (2002) Combined calcium and
vitamin D3 supplementation in elderly women: confirmation of
reversal of secondary hyperparathyroidism and hip fracture risk:
the Decalyos II study. Osteoporos Int 13:257–264
17. Dawson-Hughes B, Harris SS, Krall EA, Dallal GE (1997)
Effect of calcium and vitamin D supplementation on bone
density in men and women 65 years of age or older. N Engl J
Med 337:670–676
18. Lips P, Graafmans WC, Ooms ME, Bezemer PD, Bouter LM
(1996) Vitamin D supplementation and fracture incidence in
elderly persons. A randomized, placebo-controlled clinical trial.
Ann Intern Med 124:400–406
19. Trivedi DP, Doll R, Khaw KT (2003) Effect of four monthly oral
vitamin D3 (cholecalciferol) supplementation on fractures and
m o r t a l i t yi nm e na n dw o m e nl i v i n gi nt h ec o m m u n i t y :
randomised double blind controlled trial. BMJ 326:469
20. Heikinheimo RJ, Inkovaara JA, Harju EJ, Haavisto MV, Kaarela
RH, Kataja JM, Kokko AM, Kolho LA, Rajala SA (1992)
Annual injection of vitamin D and fractures of aged bones.
Calcif Tissue Int 51:105–110
21. Bischoff-Ferrari HA, Willett WC, Wong JB, Giovannucci E,
Dietrich T, Dawson-Hughes B (2005) Fracture prevention with
vitamin D supplementation: a meta-analysis of randomized
controlled trials. JAMA 293:2257–2264
22. BoonenS,LipsP,BouillonR,Bischoff-FerrariHA,Vanderschueren
D,HaentjensP(2007)Needforadditionalcalciumtoreducetherisk
of hip fracture with vitamin d supplementation: evidence from a
comparative metaanalysis of randomized controlled trials. J Clin
Endocrinol Metab 92:1415–1423
23. Bischoff-Ferrari HA, Willett WC, Wong JB, Stuck AE, Staehelin
HB, Orav EJ, Thoma A, Kiel DP, Henschkowski J (2009)
Prevention of nonvertebral fractures with oral vitamin D and
dose dependency: a meta-analysis of randomized controlled
trials. Arch Intern Med 169:551–561
24. Tang BM, Eslick GD, Nowson C, Smith C, Bensoussan A
(2007) Use of calcium or calcium in combination with vitamin
D supplementation to prevent fractures and bone loss in
people aged 50 years and older: a meta-analysis. Lancet
370:657–666
25. Adami S, Isaia G, Luisetto G, Minisola S, Sinigaglia L,
Gentilella R, Agnusdei D, Iori N, Nuti R (2006) Fracture
incidence and characterization in patients on osteoporosis
treatment: the ICARO study. J Bone Miner Res 21:1565–
1570
26. Rossini M, Bianchi G, Di Munno O, Giannini S, Minisola S,
Sinigaglia L, Adami S (2006) Determinants of adherence to
osteoporosis treatment in clinical practice. Osteoporos Int
17:914–921
27. Rozenberg S, Vandromme J, Kroll M, Pastijn A, Degueldre M
(1994) Osteoporosis prevention with sex hormone replacement
therapy. Int J Fertil Menopausal Stud 39:262–271
28. RossouwJE,AndersonGL,PrenticeRL,LaCroixAZ,Kooperberg
C, Stefanick ML, Jackson RD, Beresford SA, Howard BV,
Johnson KC, Kotchen JM, Ockene J (2002) Risks and benefits of
estrogen plus progestin in healthy postmenopausal women:
principal results from the Women's Health Initiative randomized
controlled trial. JAMA 288:321–333
29. Scarabin PY, Oger E, Plu-Bureau G (2003) Differential associ-
ation of oral and transdermal oestrogen-replacement therapy with
venous thromboembolism risk. Lancet 362:428–432
30. Canonico M, Bouaziz E, Carcaillon L, Verstuyft C, Guiochon-
Mantel A, Becquemont L, Scarabin PY, Estrogen and Thrombo-
embolism Risk (ESTHER) Study Group (2008) Synergism
between oral estrogen therapy and cytochrome P450 3A5*1
allele on the risk of venous thromboembolism among postmen-
opausal women. J Clin Endocrinol Metab 93:3082–3087
31. CummingsSR,Ettinger B, Delmas PD,Kenemans P, Stathopoulos
V, Verweij P, Mol-Arts M, Kloosterboer L, Mosca L, Christiansen
C, Bilezikian J, Kerzberg EM, Johnson S, Zanchetta J, Grobbee
DE, Seifert W, Eastell R (2008) The effects of tibolone in older
postmenopausal women. N Engl J Med 359:697–708
32. Gompel A, Rozenberg S, Barlow DH (2008) The EMAS 2008
update on clinical recommendations on postmenopausal hor-
mone replacement therapy. Maturitas 61:227–232
33. Lekander I, Borgström F, Ström O, Zethraeus N, Kanis JA
(2009) Cost-effectiveness of hormone therapy in the United
States. J Womens Health (Larchmt) 10:1669–1677
34. Bagger YZ, Tanko LB, Alexandersen P, Hansen HB, Mollgaard
A, Ravn P, Qvist P, Kanis JA, Christiansen C (2004) Two to
three years of hormone replacement treatment in healthy women
Osteoporos Int (2010) 21:1657–1680 1675have long-term preventive effects on bone mass and osteoporotic
fractures: the PERF study. Bone 34:728–735
35. Alexandersen P, Toussaint A, Christiansen C, Devogelaer JP,
Roux C, Fechtenbaum J, Gennari C, Reginster JY (2001)
Ipriflavone in the treatment of postmenopausal osteoporosis: a
randomized controlled trial. JAMA 285:1482–1488
36. Alekel DL, Germain AS, Peterson CT, Hanson KB, Stewart JW,
Toda T (2000) Isoflavone-rich soy protein isolate attenuates bone
loss in the lumbar spine of perimenopausal women. Am J Clin
Nutr 72:844–852
37. Hsu CS, Shen WW, Hsueh YM, Yeh SL (2001) Soy isoflavone
supplementation in postmenopausal women. Effects on plasma
lipids, antioxidant enzyme activities and bone density. J Reprod
Med 46:221–226
38. Chen YM, Ho SC, Lam SS, Ho SS, Woo JL (2003) Soy
isoflavones have a favorable effect on bone loss in Chinese
postmenopausal women with lower bone mass: a double-blind,
randomized, controlled trial. J Clin Endocrinol Metab 88:4740–
4747
39. Kreijkamp-Kaspers S, Kok L, Grobbee DE, de Haan EH,
Aleman A, Lampe JW, van der Schouw YT (2004) Effect of
soy protein containing isoflavones on cognitive function, bone
mineral density, and plasma lipids in postmenopausal women: a
randomized controlled trial. JAMA 292:65–74
40. Nikander E, Metsa-Heikkila M, Ylikorkala O, Tiitinen A (2004)
Effects of phytoestrogens on bone turnover in postmenopausal
women with a history of breast cancer. J Clin Endocrinol Metab
89:1207–1212
41. Seeman E, Crans GG, Diez-Perez A, Pinette KV, Delmas PD
(2006) Anti-vertebral fracture efficacy of raloxifene: a meta-
analysis. Osteoporos Int 17:313–316
42. Recker RR, Kendler D, Recknor CP, Rooney TW, Lewiecki EM,
Utian WH, Cauley JA, Lorraine J, Qu Y, Kulkarni PM, Gaich
CL, Wong M, Plouffe L Jr, Stock JL (2007) Comparative effects
of raloxifene and alendronate on fracture outcomes in postmen-
opausal women with low bone mass. Bone 40:843–851
43. Martino S, Cauley JA, Barrett-Connor E, Powles TJ, Mershon J,
Disch D, Secrest RJ, Cummings SR (2004) Continuing outcomes
relevant to Evista: breast cancer incidence in postmenopausal
osteoporotic women in a randomized trial of raloxifene. J Natl
Cancer Inst 96:1751–1761
44. Siris ES, Harris ST, Eastell R, Zanchetta JR, Goemaere S, Diez-
Perez A, Stock JL, Song J, Qu Y, Kulkarni PM, Siddhanti SR,
Wong M, Cummings SR (2005) Skeletal effects of raloxifene
after 8 years: results from the continuing outcomes relevant to
Evista (CORE) study. J Bone Miner Res 20:1514–1524
45. Neele SJ, Evertz R, De Valk-De RG, Roos JC, Netelenbos JC
(2002) Effect of 1 year of discontinuation of raloxifene or
estrogen therapy on bone mineral density after 5 years of
treatment in healthy postmenopausal women. Bone 30:599–603
46. Barrett-Connor E, Mosca L, Collins P, Geiger MJ, Grady D,
Kornitzer M, McNabb MA, Wenger NK (2006) Effects of
raloxifene on cardiovascular events and breast cancer in
postmenopausal women. N Engl J Med 355:125–137
47. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini
RS, Atkins JN, Bevers TB, Fehrenbacher L, Pajon ER Jr, Wade
JL 3rd, Robidoux A, Margolese RG, James J, Lippman SM,
Runowicz CD, Ganz PA, Reis SE, McCaskill-Stevens W, Ford
LG, Jordan VC, Wolmark N (2006) Effects of tamoxifen vs
raloxifene on the risk of developing invasive breast cancer and
other disease outcomes: the NSABP Study of Tamoxifen and
Raloxifene (STAR) P-2 trial. JAMA 295:2727–2741
48. Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH,
Rodriguez-Portales J, Downs RW Jr, Dequeker J, Favus M
(1995) Effect of oral alendronate on bone mineral density and the
incidence of fractures in postmenopausal osteoporosis. The
alendronate phase III osteoporosis treatment study group. N
Engl J Med 333:1437–1443
49. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson
DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R,
Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE (1996)
Randomised trial of effect of alendronate on risk of fracture in
women with existing vertebral fractures. Fracture intervention
trial research group. Lancet 348:1535–1541
50. Cummings SR, Black DM, Thompson DE, Applegate WB,
Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin
SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ (1998)
Effect of alendronate on risk of fracture in women with low bone
density but without vertebral fractures: results from the fracture
intervention trial. JAMA 280:2077–2082
51. Karpf DB, Shapiro DR, Seeman E, Ensrud KE, Johnston CC Jr,
Adami S, Harris ST, Santora AC 2nd, Hirsch LJ, Oppenheimer
L, Thompson D (1997) Prevention of nonvertebral fractures by
alendronate. A meta-analysis. Alendronate osteoporosis treat-
ment study groups. JAMA 277:1159–1164
52. Cranney A, Wells G, Willan A, Griffith L, Zytaruk N, Robinson
V, Black D, Adachi J, Shea B, Tugwell P, Guyatt G (2002) Meta-
analyses of therapies for postmenopausal osteoporosis. II. Meta-
analysis of alendronate for the treatment of postmenopausal
women. Endocr Rev 23:508–516
53. Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD,
Tonino RP, Rodriguez-Portales JA, Downs RW, Gupta J, Santora
AC, Liberman UA (2004) Ten years' experience with alendronate
for osteoporosis in postmenopausal women. N Engl J Med
350:1189–1199
54. Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S,
Quandt SA, Satterfield S, Wallace RB, Bauer DC, Palermo L,
Wehren LE, Lombardi A, Santora AC, Cummings SR (2006)
Effects of continuing or stopping alendronate after 5 years of
treatment: the Fracture Intervention Trial Long-term Extension
(FLEX): a randomized trial. JAMA 296:2927–2938
55. de Groen PC, Lubbe DF, Hirsch LJ, Daifotis A, Stephenson W,
Freedholm D, Pryor-Tillotson S, Seleznick MJ, Pinkas H, Wang
KK (1996) Esophagitis associated with the use of alendronate. N
Engl J Med 335:1016–1021
56. Schnitzer T, Bone HG, Crepaldi G, Adami S, McClung M, Kiel D,
Felsenberg D, Recker RR, Tonino RP, Roux C, Pinchera A, Foldes
AJ,GreenspanSL,LevineMA,EmkeyR,SantoraAC2nd,KaurA,
ThompsonDE,YatesJ,OrloffJJ(2000)Therapeuticequivalenceof
alendronate 70 mg once-weekly and alendronate 10 mg daily in the
treatment of osteoporosis. Alendronate Once-Weekly Study Group.
Aging (Milano) 12:1–12
57. Dansereau RJ, Crail DJ, Perkins AC (2009) In vitro
disintegration studies of weekly generic alendronate sodium
tablets (70 mg) available in the US. Curr Med Res Opin
25:449–452
58. Perkins AC, Blackshaw PE, Hay PD, Lawes SC, Atherton CT,
Dansereau RJ, Wagner LK, Schnell DJ, Spiller RC (2008)
Esophageal transit and in vivo disintegration of branded
risedronate sodium tablets and two generic formulations of
alendronic acid tablets: a single-center, single-blind, six-period
crossover study in healthy female subjects. Clin Ther 30:834–
844
59. Ringe JD, Moller G (2009) Differences in persistence, safety and
efficacy of generic and original branded once weekly bisphosph-
onates in patients with postmenopausal osteoporosis: 1-year
results of a retrospective patient chart review analysis. Rheuma-
tol Int. doi:10.1007/s00296-009-0940-5
60. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T,
Keller M, Chesnut CH 3rd, Brown J, Eriksen EF, Hoseyni MS,
Axelrod DW, Miller PD (1999) Effects of risedronate treatment
on vertebral and nonvertebral fractures in women with postmen-
1676 Osteoporos Int (2010) 21:1657–1680opausal osteoporosis: a randomized controlled trial. Vertebral
Efficacy With Risedronate Therapy (VERT) Study Group.
JAMA 282:1344–1352
61. Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C,
Brandi ML, Lund B, Ethgen D, Pack S, Roumagnac I, Eastell R
(2000) Randomized trial of the effects of risedronate on vertebral
fractures in women with established postmenopausal osteoporo-
sis. Vertebral Efficacy with Risedronate Therapy (VERT) study
group. Osteoporos Int 11:83–91
62. Watts NB, Josse RG, Hamdy RC, Hughes RA, Manhart MD,
Barton I, Calligeros D, Felsenberg D (2003) Risedronate
prevents new vertebral fractures in postmenopausal women at
high risk. J Clin Endocrinol Metab 88:542–549
63. Harrington JT, Ste-Marie LG, Brandi ML, Civitelli R, Fardellone
P, Grauer A, Barton I, Boonen S (2004) Risedronate rapidly
reduces the risk for nonvertebral fractures in women with
postmenopausal osteoporosis. Calcif Tissue Int 74:129–135
64. Sorensen OH, Crawford GM, Mulder H, Hosking DJ, Gennari C,
Mellstrom D, Pack S, Wenderoth D, Cooper C, Reginster JY
(2003) Long-term efficacy of risedronate: a 5-year placebo-
controlled clinical experience. Bone 32:120–126
65. Boonen S, McClung MR, Eastell R, El-Hajj Fuleihan G, Barton
IP, Delmas P (2004) Safety and efficacy of risedronate in
reducing fracture risk in osteoporotic women aged 80 and older:
implications for the use of antiresorptive agents in the old and
oldest old. J Am Geriatr Soc 52:1832–1839
66. McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG,
Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier
PJ, Reginster JY (2001) Effect of risedronate on the risk of hip
fracture in elderly women. Hip Intervention Program Study
Group. N Engl J Med 344:333–340
67. Cranney A, Tugwell P, Adachi J, Weaver B, Zytaruk N,
Papaioannou A, Robinson V, Shea B, Wells G, Guyatt G
(2002) Meta-analyses of therapies for postmenopausal osteopo-
rosis. III. Meta-analysis of risedronate for the treatment of
postmenopausal osteoporosis. Endocr Rev 23:517–523
6 8 .B r o w nJ P ,K e n d l e rD L ,M c C l u n gM R ,E m k e yR D ,A d a c h i
JD, Bolognese MA, Li Z, Balske A, Lindsay R (2002) The
efficacy and tolerability of risedronate once a week for the
treatment of postmenopausal osteoporosis. Calcif Tissue Int
71:103–111
69. Chesnut IC, Skag A, Christiansen C, Recker R, Stakkestad JA,
Hoiseth A, Felsenberg D, Huss H, Gilbride J, Schimmer RC,
Delmas PD (2004) Effects of oral ibandronate administered daily
or intermittently on fracture risk in postmenopausal osteoporosis.
J Bone Miner Res 19:1241–1249
70. Reginster JY, Adami S, Lakatos P, Greenwald M, Stepan JJ,
Silverman SL, Christiansen C, Rowell L, Mairon N, Bonvoisin
B, Drezner MK, Emkey R, Felsenberg D, Cooper C, Delmas PD,
Miller PD (2006) Efficacy and tolerability of once-monthly oral
ibandronate in postmenopausal osteoporosis: 2 year results from
the MOBILE study. Ann Rheum Dis 65:654–661
71. Stakkestad JA, Lakatos P, Lorenc R, Sedarati F, Neate C,
Reginster JY (2008) Monthly oral ibandronate is effective and
well tolerated after 3 years: the MOBILE long-term extension.
Clin Rheumatol 27:955–960
72. Delmas PD, Adami S, Strugala C, Stakkestad JA, Reginster JY,
Felsenberg D, Christiansen C, Civitelli R, Drezner MK, Recker
RR, Bolognese M, Hughes C, Masanauskaite D, Ward P,
Sambrook P, Reid DM (2006) Intravenous ibandronate injections
in postmenopausal women with osteoporosis: one-year results
from the dosing intravenous administration study. Arthritis
Rheum 54:1838–1846
73. Cranney A, Wells GA, Yetisir E, Adami S, Cooper C, Delmas
PD, Miller PD, Papapoulos S, Reginster JY, Sambrook PN,
Silverman S, Siris E, Adachi JD (2009) Ibandronate for the
prevention of nonvertebral fractures: a pooled analysis of
individual patient data. Osteoporos Int 20:291–297
74. Harris ST, Blumentals WA, Miller PD (2008) Ibandronate and
the risk of non-vertebral and clinical fractures in women with
postmenopausal osteoporosis: results of a meta-analysis of phase
III studies. Curr Med Res Opin 24:237–245
75. Sebba AI, Emkey RD, Kohles JD, Sambrook PN (2009)
Ibandronate dose response is associated with increases in bone
mineral density and reductions in clinical fractures: results of a
meta-analysis. Bone 44:423–427
76. Harris ST, Reginster JY, Harley C, Blumentals WA, Poston SA,
Barr CE, Silverman SL (2009) Risk of fracture in women treated
with monthly oral ibandronate or weekly bisphosphonates: the
eValuation of IBandronate Efficacy (VIBE) database fracture
study. Bone 44:758–765
77. Boonen S, Haentjens P, Vandenput L, Vanderschueren D (2004)
Preventing osteoporotic fractures with antiresorptive therapy:
implications of microarchitectural changes. J Intern Med 255:1–
12
78. Miller PD, Epstein S, Sedarati F, Reginster JY (2008) Once-
monthly oral ibandronate compared with weekly oral alendronate
in postmenopausal osteoporosis: results from the head-to-head
MOTION study. Curr Med Res Opin 24:207–213
79. von Moos R, Caspar CB, Thurlimann B, Angst R, Inauen R,
Greil R, Bergstrom B, Schmieding K, Pecherstorfer M (2008)
Renal safety profiles of ibandronate 6 mg infused over 15 and
60 min: a randomized, open-label study. Ann Oncol 19:1266–
1270
80. Body JJ, Diel IJ, Lichinitser MR, Kreuser ED, Dornoff W,
Gorbunova VA, Budde M, Bergström B (2003) Intravenous
ibandronate reduces the incidence of skeletal complications in
patients with breast cancer and bone metastases. Ann Oncol
14:1399–1405
81. Watts NB, Cooper C, Lindsay R, Eastell R, Manhart MD, Barton
IP, van Staa TP, Adachi JD (2004) Relationship between changes
in bone mineral density and vertebral fracture risk associated
with risedronate: greater increases in bone mineral density do not
relate to greater decreases in fracture risk. J Clin Densitom
7:255–261
82. Boonen S, Vanderschueren D, Venken K, Milisen K, Delforge
M, Haentjens P (2008) Recent developments in the manage-
ment of postmenopausal osteoporosis with bisphosphonates:
enhanced efficacy by enhanced compliance. J Intern Med
264:315–332
83. Gasser JA, Ingold P, Venturiere A, Shen V, Green JR (2008)
Long-term protective effects of zoledronic acid on cancellous
and cortical bone in the ovariectomized rat. J Bone Miner Res
23:544–551
84. Reid IR, Brown JP, Burckhardt P, Horowitz Z, Richardson P,
Trechsel U, Widmer A, Devogelaer JP, Kaufman JM, Jaeger P,
Body JJ, Brandi ML, Broell J, Di Micco R, Genazzani AR,
Felsenberg D, Happ J, Hooper MJ, Ittner J, Leb G, Mallmin H,
Murray T, Ortolani S, Rubinacci A, Saaf M, Samsioe G,
Verbruggen L, Meunier PJ (2002) Intravenous zoledronic acid
in postmenopausal women with low bone mineral density. N
Engl J Med 346:653–661
85. Bolland MJ, Grey AB, Horne AM, Briggs SE, Thomas MG,
Ellis-Pegler RB, Callon KE, Gamble GD, Reid IR (2008) Effects
of intravenous zoledronate on bone turnover and BMD persist
for at least 24 months. J Bone Miner Res 23:1304–1308
86. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley
JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C,
Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T,
Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR
(2007) Once-yearly zoledronic acid for treatment of postmeno-
pausal osteoporosis. N Engl J Med 356:1809–1822
Osteoporos Int (2010) 21:1657–1680 167787. Recker RR, Delmas PD, Halse J, Reid IR, Boonen S, Garcia-
Hernandez PA, Supronik J, Lewiecki EM, Ochoa L, Miller P, Hu
H, Mesenbrink P, Hartl F, Gasser J, Eriksen EF (2008) Effects of
intravenous zoledronic acid once yearly on bone remodeling and
bone structure. J Bone Miner Res 23:6–16
88. Lyles KW, Colon-Emeric CS, Magaziner JS, Adachi JD, Pieper
CF, Mautalen C, Hyldstrup L, Recknor C, Nordsletten L, Moore
KA, Lavecchia C, Zhang J, Mesenbrink P, Hodgson PK, Abrams
K, Orloff JJ, Horowitz Z, Eriksen EF, Boonen S (2007)
Zoledronic acid and clinical fractures and mortality after hip
fracture. N Engl J Med 357:1799–1809
89. Colon-Emeric CS, Mesenbrink P, Lyles KW, Pieper CF, Boonen
S, Delmas P, Eriksen E, Magaziner J (2009) Potential mediators
of the mortality reduction with zoledronic acid after hip fracture.
J Bone Miner Res. doi:10.1359/jbmr.090704
90. Recker RR, Lewiecki EM, Miller PD, Reiffel J (2009) Safety of
bisphosphonates in the treatment of osteoporosis. Am J Med
122:S22–S32
91. Loke YK, Jeevanantham V, Singh S (2009) Bisphosphonates and
atrial fibrillation: systematic review and meta-analysis. Drug Saf
32:219–228
92. Boonen S, Sellmeyer DE, Lippuner K, Orlov-Morozov A,
Abrams K, Mesenbrink P, Eriksen EF, Miller PD (2008) Renal
safety of annual zoledronic acid infusions in osteoporotic
postmenopausal women. Kidney Int 74:641–648
93. Weycker D, Macarios D, Edelsberg J, Oster G (2006) Compli-
ance with drug therapy for postmenopausal osteoporosis.
Osteoporos Int 17:1645–1652
94. Rabenda V, Vanoverloop J, Fabri V, Mertens R, Sumkay F,
Vannecke C, Deswaef A, Verpooten GA, Reginster JY (2008)
Low incidence of anti-osteoporosis treatment after hip fracture. J
Bone Joint Surg Am 90:2142–2148
95. Ettinger MP, Gallagher R, MacCosbe PE (2006) Medication
persistence with weekly versus daily doses of orally administered
bisphosphonates. Endocr Pract 12:522–528
96. Cotte FE, Fardellone P, Mercier F, Gaudin AF, Roux C (2010)
Adherence to monthly and weekly oral bisphosphonates in
women with osteoporosis. Osteoporos Int 21:145–55
97. Khan AA, Sandor GK, Dore E, Morrison AD, Alsahli M, Amin
F, Peters E, Hanley DA, Chaudry SR, Lentle B, Dempster DW,
Glorieux FH, Neville AJ, Talwar RM, Clokie CM, Mardini MA,
Paul T, Khosla S, Josse RG, Sutherland S, Lam DK, Carmichael
RP, Blanas N, Kendler D, Petak S, Ste-Marie LG, Brown J,
Evans AW, Rios L, Compston JE (2009) Bisphosphonate
associated osteonecrosis of the jaw. J Rheumatol 36:478–490
98. Allen MR, Burr DB (2009) The pathogenesis of bisphosphonate-
related osteonecrosis of the jaw: so many hypotheses, so few
data. J Oral Maxillofac Surg 67:61–70
99. Lenart BA, Lorich DG, Lane JM (2008) Atypical fractures of the
femoral diaphysis in postmenopausal women taking alendronate.
New Engl J Med 358:1304–1306
100. Schneider JP (2009) Bisphosphonates and low-impact femoral
fractures: current evidence on alendronate-fracture risk. Geriat-
rics 64:18–23
101. Neviaser AS, Lane JM, Lenart BA, Edobor-Osula F, Lorich DG
(2008) Low-energy femoral shaft fractures associated with
alendronate use. J Orthop Trauma 22:346–350
102. Kwek EB, Goh SK, Koh JS, Png MA, Howe TS (2008) An
emerging pattern of subtrochanteric stress fractures: a long-term
complication of alendronate therapy? Injury 39:224–231
103. Chapurlat RD, Arlot M, Burt-Pichat B, Chavassieux P, Roux JP,
Portero-Muzy N, Delmas P (2007) Microcrack frequency and
bone turnover in osteoporotic women on long term bisphosph-
onates: a bone biopsy study. J Bone Miner Res 22:1502–1509
104. Stepan JJ, Burr DB, Pavo I, Sipos A, Michalska D, Li J,
Fahrleitner-Pammer A, Petto H, Westmore M, Michalsky D, Sato
M, Dobnig H (2007) Low bone mineral density is associated
with bone microdamage accumulation in postmenopausal wom-
en with osteoporosis. Bone 41:378–385
105. Abrahamsen B, Eiken P, Eastell R (2009) Subtrochanteric and
diaphyseal femur fractures in patients treated with alendronate: a
register-based national cohort study. J Bone Miner Res 24:1095–
1102
106. Dempster DW, Cosman F, Parisien M, Shen V, Lindsay R (1993)
Anabolic actions of parathyroid hormone on bone. Endocr Rev
14:690–709
107. Canalis E, Giustina A, Bilezikian JP (2007) Mechanisms of
anabolic therapies for osteoporosis. N Engl J Med 357:905–916
108. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA,
Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant
HK, Wang O, Mitlak BH (2001) Effect of parathyroid hormone
(1-34) on fractures and bone mineral density in postmenopausal
women with osteoporosis. N Engl J Med 344:1434–1441
109. Miller PD, Bilezikian JP, Diaz-Curiel M, Chen P, Marin F, Krege
JH, Wong M, Marcus R (2007) Occurrence of hypercalciuria in
patients with osteoporosis treated with teriparatide. J Clin
Endocrinol Metab 92:3535–3541
110. McClung MR, San Martin J, Miller PD, Civitelli R, Bandeira F,
Omizo M, Donley DW, Dalsky GP, Eriksen EF (2005) Opposite
bone remodeling effects of teriparatide and alendronate in
increasing bone mass. Arch Intern Med 165:1762–1768
111. Chen P, Satterwhite JH, Licata AA, Lewiecki EM, Sipos AA,
Misurski DM, Wagman RB (2005) Early changes in biochemical
markers of bone formation predict BMD response to teriparatide
in postmenopausal women with osteoporosis. J Bone Miner Res
20:962–970
112. Dobnig H, Sipos A, Jiang Y, Fahrleitner-Pammer A, Ste-Marie
LG, Gallagher JC, Pavo I, Wang J, Eriksen EF (2005) Early
changes in biochemical markers of bone formation correlate with
improvements in bone structure during teriparatide therapy. J
Clin Endocrinol Metab 90:3970–3977
113. Marcus R, Wang O, Satterwhite J, Mitlak B (2003) The
skeletal response to teriparatide is largely independent of age,
initial bone mineral density, and prevalent vertebral fractures
in postmenopausal women with osteoporosis. J Bone Miner
Res 18:18–23
114. Dawson-Hughes B, Chen P, Krege JH (2007) Response to
teriparatide in patients with baseline 25-hydroxyvitamin D insuffi-
ciency or sufficiency. J Clin Endocrinol Metab 92:4630–4636
115. Lindsay R, Scheele WH, Neer R, Pohl G, Adami S, Mautalen C,
Reginster JY, Stepan JJ, Myers SL, Mitlak BH (2004) Sustained
vertebral fracture risk reduction after withdrawal of teriparatide
in postmenopausal women with osteoporosis. Arch Intern Med
164:2024–2030
116. Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan
JA, Lang TF, Garnero P, Bouxsein ML, Bilezikian JP, Rosen CJ
(2003) The effects of parathyroid hormone and alendronate alone
or in combination in postmenopausal osteoporosis. N Engl J Med
349:1207–1215
117. Deal C, Omizo M, Schwartz EN, Eriksen EF, Cantor P, Wang J,
Glass EV, Myers SL, Krege JH (2005) Combination teriparatide
and raloxifene therapy for postmenopausal osteoporosis: results
from a 6-month double-blind placebo-controlled trial. J Bone
Miner Res 20:1905–1911
118. Ettinger B, San Martin J, Crans G, Pavo I (2004) Differential
effects of teriparatide on BMD after treatment with raloxifene or
alendronate. J Bone Miner Res 19:745–751
119. Hodsman AB, Hanley DA, Ettinger MP, Bolognese MA, Fox J,
Metcalfe AJ, Lindsay R (2003) Efficacy and safety of human
parathyroid hormone-(1-84) in increasing bone mineral density
in postmenopausal osteoporosis. J Clin Endocrinol Metab
88:5212–5220
1678 Osteoporos Int (2010) 21:1657–1680120. Greenspan SL, Bone HG, Ettinger MP, Hanley DA, Lindsay R,
Zanchetta JR, Blosch CM, Mathisen AL, Morris SA, Marriott
TB (2007) Effect of recombinant human parathyroid hormone
(1-84) on vertebral fracture and bone mineral density in
postmenopausal women with osteoporosis: a randomized trial.
Ann Intern Med 146:326–339
121. Reginster JY, Malaise O, Neuprez A, Bruyere O (2007)
Strontium ranelate in the prevention of osteoporotic fractures.
Int J Clin Pract 61:324–328
122. Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE,
Spector TD, Cannata J, Balogh A, Lemmel EM, Pors-Nielsen S,
Rizzoli R, Genant HK, Reginster JY (2004) The effects of
strontium ranelate on the risk of vertebral fracture in women with
postmenopausal osteoporosis. N Engl J Med 350:459–468
123. Canalis E, Hott M, Deloffre P, Tsouderos Y, Marie PJ (1996) The
divalent strontium salt S12911 enhances bone cell replication
and bone formation in vitro. Bone 18:517–523
124. Baron R, Tsouderos Y (2002) In vitro effects of S12911-2 on
osteoclast function and bone marrow macrophage differentiation.
Euro J Pharmacol 450:11–17
125. Takahashi N, Sasaki T, Tsouderos Y, Suda T (2003) S 12911-2
inhibits osteoclastic bone resorption in vitro. J Bone Miner Res
18:1082–1087
126. Hurtel-Lemaire AS, Mentaverri R, Caudrillier A, Cournarie F,
Wattel A, Kamel S, Terwilliger EF, Brown EM, Brazier M
(2009) The calcium-sensing receptor is involved in strontium
ranelate-induced osteoclast apoptosis. New insights into the
associated signaling pathways. J Biol Chem 284:575–584
127. Bonne lye E, Chabadel A, Saltel F, Jurdic P (2008) Dual effect of
strontium ranelate: stimulation of osteoblast differentiation and
inhibition of osteoclast formation and resorption in vitro. Bone
42:129–138
128. Bain SD, Jerome C, Shen V, Dupin-Roger I, Ammann P (2009)
Strontium ranelate improves bone strength in ovariectomized rat
by positively influencing bone resistance determinants. Osteo-
poros Int 20:1417–1428
129. Reginster JY, Seeman E, De Vernejoul MC, Adami S, Compston
J, Phenekos C, Devogelaer JP, Curiel MD, Sawicki A, Goemaere
S, Sorensen OH, Felsenberg D, Meunier PJ (2005) Strontium
ranelate reduces the risk of nonvertebral fractures in postmeno-
pausal women with osteoporosis: Treatment of Peripheral
Osteoporosis (TROPOS) study. J Clin Endocrinol Metab
90:2816–2822
130. Reginster JY, Spector T, Badurski J (2002) A short-term run-in
study can significantly contribute to increasing the quality of
long-term osteoporosis trials. The strontium ranelate phase III
program. Osteoporos Int 13:S30
131. Reginster JY, Felsenberg D, Boonen S, Diez-Perez A, Rizzoli R,
Brandi ML, Spector TD, Brixen K, Goemaere S, Cormier C,
Balogh A, Delmas PD, Meunier PJ (2008) Effects of long-term
strontium ranelate treatment on the risk of nonvertebral and
vertebral fractures in postmenopausal osteoporosis: results of a
five-year, randomized, placebo-controlled trial. Arthritis Rheum
58:1687–1695
132. Reginster JY, Sawicki A, Roces-Varela (2008) Strontium
ranelate: 8 years efficacy on vertebral and nonvertebral fractures
in post menopausal osteoporotic women. Osteoporos Int 19:
S131–S132
133. Roux C, Reginster JY, Fechtenbaum J, Kolta S, Sawicki A,
Tulassay Z, Luisetto G, Padrino JM, Doyle D, Prince R,
Fardellone P, Sorensen OH, Meunier PJ (2006) Vertebral fracture
risk reduction with strontium ranelate in women with postmen-
opausal osteoporosis is independent of baseline risk factors. J
Bone Miner Res 21:536–542
134. Seeman E, Vellas B, Benhamou C, Aquino JP, Semler J,
Kaufman JM, Hoszowski K, Varela AR, Fiore C, Brixen K,
Reginster JY, Boonen S (2006) Strontium ranelate reduces the
risk of vertebral and nonvertebral fractures in women eighty
years of age and older. J Bone Miner Res 21:1113–1120
135. Seeman E, Devogelaer JP, Lorenc R, Spector T, Brixen K,
Balogh A, Stucki G, Reginster JY (2008) Strontium ranelate
reduces the risk of vertebral fractures in patients with osteopenia.
J Bone Miner Res 23:433–438
136. Bruyere O, Roux C, Detilleux J, Slosman DO, Spector TD,
FardelloneP, BrixenK, Devogelaer JP, Diaz-Curiel M,Albanese C,
Kaufman JM, Pors-Nielsen S, Reginster JY (2007) Relationship
betweenbonemineraldensitychangesandfractureriskreductionin
patients treated with strontium ranelate. J Clin Endocrinol Metab
92:3076–3081
137. Shea B, Wells G, Cranney A, Zytaruk N, Robinson V, Griffith L,
Hamel C, Ortiz Z, Peterson J, Adachi J, Tugwell P, Guyatt G;
Osteoporosis Methodology Group; Osteoporosis Research Adviso-
ry Group (2004) Calcium supplementation on bone loss in
postmenopausal women. Cochrane Database Syst Rev CD004526
138. European Medicines Agency (EMEA) (2007) Question and
answers on the safety of Protelos/Osseor (strontium ranelate) Ref.
EMEA/534613/2007. Available via http://www.emea.europa.eu/
humandocs/PDFs/EPAR/protelos/Protelos_Q&A_53461307en.
pdf. Accessed 1 Oct 2008
139. Grosso A, Douglas I, Hingorani A, MacAllister R, Smeeth L
(2008) Post-marketing assessment of the safety of strontium
ranelate; a novel case-only approach to the early detection of
adverse drug reactions. Br J Clin Pharmacol 66:689–694
140. Tas S, Simonart T (2003) Management of drug rash with
eosinophilia and systemic symptoms (DRESS syndrome): an
update. Dermatology 206:353–356
141. Sainz M, del Pozo JG, Arias LH, Carvajal A (2009) Strontium
ranelate may cause alopecia. BMJ 338:b1494
142. Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin
TJ (1999) Modulation of osteoclast differentiation and function
by the new members of the tumor necrosis factor receptor and
ligand families. Endocr Rev 20:345–357
143. Li J, Sarosi I, Yan XQ, Morony S, Capparelli C, Tan HL,
McCabe S, Elliott R, Scully S, Van G, Kaufman S, Juan SC,
Sun Y, Tarpley J, Martin L, Christensen K, McCabe J,
Kostenuik P, Hsu H, Fletcher F, Dunstan CR, Lacey DL,
Boyle WJ (2000) RANK is the intrinsic hematopoietic cell
surface receptor that controls osteoclastogenesis and regula-
tion of bone mass and calcium metabolism. Proc Natl Acad
Sci U S A 97:1566–1571
144. SimonetWS,Lacey DL,Dunstan CR,KelleyM,Chang MS,Luthy
R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G,
DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J,
Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison
W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle
WJ(1997)Osteoprotegerin:anovelsecretedproteininvolvedinthe
regulation of bone density. Cell 89:309–319
145. Body JJ, Greipp P, Coleman RE, Facon T, Geurs F, Fermand JP,
Harousseau JL, Lipton A, Marriette X, Williams CD, Nakanishi
A, Holloway D, Dunstan CR, Bekker PJ (2003) A phase I study
of AMGN-0007, a recombinant osteoprotegerin construct, in
patients with multiple myeloma or breast carcinoma related bone
metastases. Cancer 97:887–892
146. Bekker PJ, Holloway DL, Rasmussen AS, Murphy R, Martin
SW, Leese PT, Holmes GB, Dunstan CR, DePaoli AM (2004) A
single-dose placebo-controlled study of AMG 162, a fully
human monoclonal antibody to RANKL, in postmenopausal
women. J Bone Miner Res 19:1059–1066
147. Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Spelsberg TC,
Riggs BL (1999) Estrogen stimulates gene expression and
protein production of osteoprotegerin in human osteoblastic
cells. Endocrinology 140:4367–4370
Osteoporos Int (2010) 21:1657–1680 1679148. Eghbali-Fatourechi G, Khosla S, Sanyal A, Boyle WJ, Lacey
DL, Riggs BL (2003) Role of RANK ligand in mediating
increased bone resorption in early postmenopausal women. J
Clin Invest 111:1221–1230
149. McClungMR,LewieckiEM,CohenSB,BologneseMA,Woodson
GC, Moffett AH, Peacock M, Miller PD, Lederman SN, Chesnut
CH, Lain D, Kivitz AJ, Holloway DL, Zhang C, Peterson MC,
Bekker PJ (2006) Denosumab in postmenopausal women with low
bone mineral density. N Engl J Med 354:821–831
150. Lewiecki EM, Miller PD, McClung MR, Cohen SB, Bolognese
MA, Liu Y, Wang A, Siddhanti S, Fitzpatrick LA (2007) Two-
year treatment with denosumab (AMG 162) in a randomized
phase 2 study of postmenopausal women with low BMD. J Bone
Miner Res 22:1832–1841
151. Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R,
Reid IR et al (2009) Denosumab for prevention of fractures in
postmenopausal women with osteoporosis. New Engl J Med
361:756–765
152. Brown JP, Prince RL, Deal C, Recker RR, Kiel DP, de Gregorio
LH, Hadji P, Hofbauer LC, Alvaro-Gracia JM, Wang H, Austin
M, Wagman RB, Newmark R, Libanati C, San Martin J, Bone
HG (2009) Comparison of the effect of denosumab and
alendronate on BMD and biochemical markers of bone turnover
in postmenopausal women with low bone mass: a randomized,
blinded, phase 3 trial. J Bone Miner Res 24:153–161
153. Cummings S, Eastell R, Ensrud KE, Reid DM, Vukicevic S, La
Croix A et al (2008) The effects of lasofoxifene on fractures and
breast cancer: 3-year results from the PEARL trial. J Bone Miner
Res 23:S81, Abstr. 1288
154. Downs R, Moffett AH, Ghosh A, Cox DA, Harper K (2008)
Effects of arzoxifene on bone turnover and safety in postmen-
opausal women with low bone mass: results from a 6-month
phase 2 study. J Bone Miner Res 23:S470–S471
155. Silverman SL, Christiansen C, Genant HK, Vukicevic S,
Zanchetta JR, de Villiers TJ, Constantiene GD, Chines AA
(2008) Efficacy of bazedoxifene in reducing new vertebral
fracture risk in postmenopausal women with osteoporosis:
results from a 3-year, randomized, placebo-, and active-
controlled clinical trial. J Bone Miner Res 23:1923–1934
156. Stroup GB, Lark MW, Veber DF, Bhattacharyya A, Blake S,
Dare LC, Erhard KF, Hoffman SJ, James IE, Marquis RW, Ru Y,
Vasko-Moser JA, Smith BR, Tomaszek T, Gowen M (2001)
Potent and selective inhibition of human cathepsin K leads to
inhibition of bone resorption in vivo in a nonhuman primate. J
Bone Miner Res 16:1739–1746
157. McClung MR, Bone H, Cosman E, Roux C, Verbruggen N,
Hustad C, DaSilva C, Santora A, Ince A (2008) A
randomized, double-blind, placebo-controlled study of odana-
catib (MK-822) in the treatment of postmenopausal women
with low bone mineral density: 24-month results. J Bone
Miner Res 23:S82
158. Li X, Ominski MS, Warmington KS, Morony S, Gong J, Cao J,
Gao Y, Shalhoub V, Tipton B, Haldankar R, Chen Q, Winters A,
Boone T, Geng Z, Niu QT, Ke HZ, Kostenuik PJ, Simonet WS,
Lacey DL, Paszty C (2009) Sclerostin antibody treatment
increases bone formation, bone mass and bone strength in a rat
model of postmenopausal osteoporosis. J Bone Miner Res
24:578–588
1680 Osteoporos Int (2010) 21:1657–1680